Immune response suppressants
By inhibiting CD96 binding to CD155 and CD111, the immune response of IL-17-producing cells is suppressed, effectively reducing IL-17 production and alleviating autoimmune and inflammatory diseases.
Patent Information
- Application Number
- JP2021553518
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-30
- Filing Date
- 2020-10-22
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2040-10-22
AI Technical Summary
IL-17 production by immune cells leads to autoimmune diseases and chronic inflammatory conditions, and existing treatments like IL-17 inhibitors have limitations, necessitating a deeper understanding of immune response mechanisms to effectively suppress IL-17 production.
Inhibiting the binding of CD96 to CD155 and CD111 proteins using agents such as anti-CD96 antibodies to suppress the immune response of IL-17-producing cells, particularly γδT cells, thereby reducing IL-17 and IL-22 production.
This approach effectively suppresses IL-17 production, alleviating symptoms of autoimmune diseases like psoriasis and other inflammatory conditions by targeting the immune response mechanism of IL-17-producing cells.
Smart Images

Figure 0007576847000001 
Figure 0007576847000002 
Figure 0007576847000003
Abstract
Description
[Technical field]
[0001] The present invention relates to an immune response suppressant. [Background technology]
[0002] There are two types of immunity: innate immunity, which recognizes and immediately eliminates foreign substances that enter the body, and adaptive immunity, in which lymphocytes recognize information about the invading foreign substance and eliminate that specific substance based on that information. The types of immune cells that play a key role in each type of immunity are different. For example, the cells responsible for innate immunity are macrophages, neutrophils, mast cells, dendritic cells, etc., and are characterized by their rapid response to infection by recognizing molecular structures common to pathogens or being activated by cytokines. On the other hand, the cells responsible for adaptive immunity are T cells and B cells, which are activated when T cell receptors and B cell receptors recognize specific pathogens, and are characterized by their slow but strong response to infection.
[0003] Most of the T cells in human peripheral blood are αβT cells expressing a T cell receptor (TCR) composed of two glycoproteins called α and β chains, but a few percent of the T cells express a TCR composed of γ and δ chains. Although γδT cells are a type of T cell, they are considered to be cells located at the boundary between innate immunity and adaptive immunity because they are instantly activated by cytokines and produce inflammatory cytokines. γδT cells are frequently localized in tissues exposed to foreign antigens, such as the intestine, lungs, genital epithelium, and skin. IL (interleukin)-17 and IFN (interferon)-γ are known to be inflammatory cytokines produced by γδT cells.
[0004] Most mature T cells in human peripheral blood express either CD4 or CD8 as a marker molecule on the cell surface. T cells expressing CD4 function as helper T cells, while T cells expressing CD8 function as killer T cells. Two subsets of helper T cells, type 1 helper T cells (Th1 cells) and type 2 helper T cells (Th2 cells), have long been known. Th1 cells produce IFN-γ and induce macrophage activation, and are primarily involved in cellular immunity and the elimination of intracellular parasites. Th2 cells are involved in humoral immunity and infection defense against extracellular parasites by inducing differentiation of eosinophils through the production of IL-5 and IL-13. Later, IL-17-producing T cells were discovered and named Th17 cells, and came to be recognized as a subset distinct from Th1 and Th2 cells. It has become clear that Th17 cells produce IL-17, GM-CSF (granulocyte-monocyte colony-stimulating factor) and IL-22, and play a central role in autoimmune and allergic responses, and in defense against extracellular bacterial infections.
[0005] ILC (innate lymphoid cell, ILC) cells are a recently identified group of lymphocytes distinct from T cells and B cells, and are widely present in various tissues. They are classified into groups 1 to 3 based on the cytokines they produce. Group 1 ILC (ILC1) is characterized by the production of cytokines similar to Th1 cells, namely IFN-γ. Group 2 ILC (ILC2) has a cytokine production similar to Th2 cells, producing IL-5 and IL-13. Group 3 ILC (ILC3) has a cytokine production similar to Th17 cells, producing IL-17 and IL-22.
[0006] IL-17, which is produced in the immune response of cells such as γδT cells, Th17 cells, and ILC3 cells, is a type of inflammatory cytokine. While it plays an important role in preventing fungal infection, it is known to act on various cells such as fibroblasts, epithelial cells, vascular endothelial cells, and macrophages to induce various factors such as inflammatory cytokines, chemokines, and cell adhesion factors, thereby inducing inflammation. Therefore, if the production of IL-17 is not properly controlled, autoimmune diseases and chronic inflammatory diseases can be caused. It is known that IL-17 is overproduced in autoimmune diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis, scleroderma, and lupus. In addition, it has been reported that IL-17-producing cells are involved in the aggravation of pathology in collagen-induced arthritis models used as models of rheumatoid arthritis, EAE (Experimental autoimmune encephalomyelitis) models used as models of multiple sclerosis and acute disseminated encephalomyelitis, atopic dermatitis models, DMBA / TPA-induced skin tumor models, and the like (Non-Patent Document 1). Furthermore, it has been reported that IL-17-producing γδ T cells are involved in the aggravation of pathology in cerebral infarction models and nephritis models (Non-Patent Documents 2 and 3). It has also been reported that the expression level of IL-17 is increased in patients with lung injury and pulmonary fibrosis, and that IL-17 production by γδ T cells, Th17 cells, ILC3 cells, and the like is involved in pathology (Non-Patent Document 4).
[0007] Therefore, IL-17 is considered to be a target for treating or preventing these diseases. In fact, IL-17 inhibitors including anti-IL-17A antibody preparations secukinumab and ixekizumab, and anti-IL-17A receptor antibody preparation brodalumab have been developed and are used to treat psoriasis (Non-Patent Document 5).
[0008] Incidentally, CD96 is a type I transmembrane glycoprotein belonging to the immunoglin superfamily, and has been reported to be expressed in cells originating from the hematopoietic system, particularly NK cells (natural killer cells), αβT cells, and γδT cells (Non-Patent Document 6). CD96 uses CD155 or CD111 expressed on target cells as its ligand, and is activated by these. It is also known that CD96 expressed on NK cells is involved in tumor immunity as an immune checkpoint receptor that transmits inhibitory signals (Non-Patent Document 7). However, the role that CD96 plays in the immune control system is still largely unknown. [Prior art documents] [Non-patent literature]
[0009] [Non-Patent Document 1] Monin et. al., IL-17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications, Cold Spring Hab Pespect Biol., 2018, 10 (4) [Non-Patent Document 2] Shichita et. al., Pivotal role of cerebral interleukin-17-producing gamma-delta-T-cells in the delayed phase of ischemic brain injury. Nature Medicine, 2009, vol.15, number 8, 946-951 [Non-Patent Document 3] Turner et. al.,IL-17A Production by Renal Gamma-delta-T-cells Promotes Kidney injury in Crescentic GN. J Am Soc Nephrol, 2012, 23. 1486-1495 [Non-Patent Document 4] Gurczynski et al., IL-17 in the lung: the good, the bad, and the ugly, Am J Physiol Lung Cell Mol Physiol, 2018, 314. L6-L16 [Non-Patent Document 5] Psoriasis Biological Agents Review Committee of the Japanese Dermatological Association, Japanese Dermatological Association Manual "Guidance for the Use of Biological Agents in Psoriasis (2019 Edition)" [Non-Patent Document 6] Georgiev et. al., Coming of Age: CD96 Emerges as Modulator of Immune Responses, frontiers in Immunology, 2018, Vol.9, Article 1072 [Non-Patent Document 7] Chan et. al., The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions, Nature Immunology, 2014, volume 15,431-438 Summary of the Invention [Problem to be solved by the invention]
[0010] The present inventors have considered that if the immune response mechanism of IL-17-producing cells can be elucidated and the production of IL-17 can be suppressed by inhibiting a part of the mechanism, it would be effective in treating pathologies involving cells that produce IL-17. Thus, the present invention aims to elucidate the immune response mechanism of IL-17-producing cells that cause pathologies such as psoriasis, and to provide an immune response suppressant for suppressing the immune response of IL-17-producing cells, and further a pharmaceutical product for treating or preventing diseases or pathologies involving the immune response of IL-17-producing cells, as the first and second aspects of the present invention. In addition, the present invention aims to provide a method for inducing an immune response in γδ T cells and the like, as the third aspect of the present invention. Furthermore, the present invention aims to provide a method for evaluating a pharmaceutical product (candidate substance) for treating or preventing diseases or pathologies involving the immune response of IL-17-producing cells, as the fourth aspect of the present invention. In the fifth aspect of the present invention, the present invention aims to provide a method for inducing an immune response in γδ T cells and the like to produce IL-17. [Means for solving the problem]
[0011] The present inventors have conducted extensive research to solve the above problems, and as a result have found that the above problems can be solved by providing the following configuration, which has led to the completion of the present invention. The present invention relates to, for example, the following [1] to
[11] . [1] An agent for suppressing the immune response of IL-17-producing cells, comprising a substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111. [2] The immune response suppressor of IL-17-producing cells according to [1], wherein the substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111 is an anti-CD96 antibody. [3] The immune response suppressor of IL-17-producing cells according to [1] or [2], wherein the IL-17-producing cells are γδ T cells. [4] The immune response inhibitor of IL-17-producing cells described in any of [1] to [3], wherein the immune response inhibitor of IL-17-producing cells is an IL-17 production inhibitor or an IL-22 production inhibitor. [5] A pharmaceutical for treating or preventing a disease or pathology involving the immune response of IL-17-producing cells, comprising an immune response inhibitor of IL-17-producing cells according to any one of [1] to [4]. [6] The pharmaceutical according to [5], wherein the disease or pathology involving the immune response of the IL-17-producing cells is psoriasis, rheumatoid arthritis, atopic dermatitis, multiple sclerosis, cerebral infarction, nephritis, lung injury, pulmonary fibrosis or skin tumor. [7] A method comprising the step (A) of culturing at least one of γδ T cells and CD4 positive T cells together with IL-23, an anti-CD3 antibody capable of stimulating the TCR / CD3 complex, and an anti-CD96 antibody capable of stimulating CD96. [8] The method according to [7], further comprising a step (B) of evaluating IL-17 after carrying out the step (A). [9] A method for evaluating a pharmaceutical agent for treating or preventing a disease or pathology involving the immune response of IL-17-producing cells, comprising the method according to [8].
[10] The method for evaluating a pharmaceutical product according to [9], wherein the disease or pathology involving the immune response of IL-17-producing cells is psoriasis, rheumatoid arthritis, atopic dermatitis, multiple sclerosis, cerebral infarction, nephritis, lung injury, pulmonary fibrosis or skin tumor.
[11] A method for producing IL-17, comprising the step (A) of culturing at least one of γδ T cells and CD4 positive T cells together with IL-23, an anti-CD3 antibody capable of stimulating the TCR / CD3 complex, and an anti-CD96 antibody capable of stimulating CD96. Effect of the Invention
[0012] According to the present invention, it is possible to provide an immune response suppressant for suppressing the immune response of IL-17-producing cells that cause pathologies such as psoriasis, and further a pharmaceutical product for treating or preventing a disease or pathology involving the immune response of IL-17-producing cells. It is also possible to provide a method for inducing an immune response in γδ T cells. It is also possible to provide a method for evaluating a pharmaceutical product for treating or preventing a disease or pathology involving the immune response of IL-17-producing cells. It is also possible to provide a method for inducing an immune response in γδ T cells to produce IL-17. [Brief description of the drawings]
[0013] [Figure 1] FIG. 1 shows photographs of the backs of wild-type and CD96-deficient mice in an imiquimod-induced psoriasis model taken 3 days after the start of imiquimod application. [Diagram 2] 2 is a graph showing erythema, scale, and skin thickness of the back skin in an imiquimod-induced psoriasis model on day 3 after starting imiquimod application. The vertical axis shows erythema score, scale score, and skin thickness (μm), respectively. [Diagram 3] FIG. 3 is a photograph showing HE staining of a tissue specimen from the back skin of a mouse in an imiquimod-induced psoriasis model, taken 3 days after the start of imiquimod application. [Figure 4] FIG. 4 is a graph showing the epidermal thickness of mouse back skin 3 days after the start of imiquimod application in an imiquimod-induced psoriasis model. [Diagram 5] 5 is a graph showing the number of neutrophils in the back skin of mice in an imiquimod-induced psoriasis model 3 days after the start of imiquimod application. The vertical axis shows the number of neutrophils per cm2. [Figure 6] FIG. 6 is a graph showing the relative expression level of IL-23 in myeloid cells in the dorsal skin of mice in an imiquimod-induced psoriasis model. [Figure 7] FIG. 7 is a graph showing the relative expression levels of IL-23R and IL-12β1 in γδ T cells in mouse dorsal skin in an imiquimod-induced psoriasis model. [Figure 8] FIG. 8 is a graph showing the relative expression levels of IL-17 and IL-22 in γδ T cells in mouse dorsal skin in an imiquimod-induced psoriasis model. [Figure 9] FIG. 9 is a graph showing the percentage of IL-17-producing γδ T cells in mouse dorsal skin and the number of IL-17-producing cells in an imiquimod-induced psoriasis model. [Figure 10]FIG. 10 is a graph showing the difference in the relative expression level of IL-17 increased by IL-23 in spleen-derived γδ T cells from wild-type mice, depending on the presence or absence of stimulation with immobilized CD96 antibody. [Figure 11] FIG. 11 is a graph showing the difference in the relative expression level of IL-17 increased by CD3 signal and IL-23 in spleen-derived γδ T cells from wild-type mice, depending on the presence or absence of stimulation with immobilized anti-CD96 antibody. [Figure 12] 12 is a graph showing the difference in activation of wild-type mouse spleen-derived γδ T cells by CD3 signaling and IL-23 in the presence or absence of stimulation with immobilized anti-CD96 antibody. The vertical axis shows the average fluorescence value. [Figure 13] 13 shows the results of flow cytometry analysis confirming the expression of CD96 in human PBMC-derived γδ T cells and human PBMC-derived CD4+ T cells. The horizontal axis shows the expression intensity of CD96, and the vertical axis shows the cell number. [Figure 14] FIG. 14 is a graph showing the difference in the amount of IL-17 produced, which is increased by CD3 signaling and IL-23, in γδ T cells derived from human PBMC obtained from seven healthy individuals, depending on whether or not stimulation with immobilized anti-CD96 antibody is performed. [Figure 15] 15 is a graph showing the difference in activation by CD3 signals in human PBMC-derived γδ T cells obtained from six healthy individuals, with or without stimulation with immobilized anti-CD96 antibody. The vertical axis shows the average fluorescence value. [Figure 16] FIG. 16 is a graph showing the difference in the amount of IL-17 produced, which is increased by CD3 signaling and IL-23, in human PBMC-derived CD4+ T cells obtained from eight healthy individuals, depending on whether or not stimulation with immobilized anti-CD96 antibody is performed. [Figure 17] 17 is a graph showing the difference in activation by CD3 signals in human PBMC-derived CD4+ T cells obtained from six healthy individuals, with or without stimulation with immobilized anti-CD96 antibody. The vertical axis shows the average fluorescence value. [Figure 18]FIG. 18 is a graph showing the difference in IL-17 production, which is increased by stimulation with CD3 signals, IL-23, and CD155, in CD4+ T cells derived from human PBMC obtained from healthy individuals, depending on the presence or absence of an anti-CD96 neutralizing antibody. [Figure 19] 19 shows the results of flow cytometry analysis confirming the binding specificity of anti-mouse CD96 neutralizing antibody (TX111.2) to CD96. The horizontal axis indicates the expression intensity of CD96, and the vertical axis indicates the cell number. [Figure 20] 20 is a graph showing that an anti-mouse CD96 neutralizing antibody (TX111.2) inhibits the binding between CD96 and CD155 in a concentration-dependent manner. The vertical axis shows the average fluorescence value. [Figure 21] FIG. 21 shows the amino acid sequences of the heavy and light chain variable regions of an anti-mouse CD96 neutralizing antibody (TX111.2). [Figure 22] FIG. 22 is a schematic diagram showing the protocol of an experiment in which an anti-mouse CD96 neutralizing antibody (TX111.2) was prophylactically administered to a mouse model of imiquimod-induced psoriasis. [Diagram 23] FIG. 23 shows photographs of the backs of a control antibody (cIg)-administered group and a TX111.2-administered group, taken 3 days after the start of imiquimod application, in an experiment of preventive administration of an anti-mouse CD96 neutralizing antibody (TX111.2) to an imiquimod-induced psoriasis model mouse. [Figure 24] 24 is a graph showing erythema, scale, and skin thickness of the back skin on day 4 after the start of imiquimod application in an experiment of preventive administration of anti-mouse CD96 neutralizing antibody (TX111.2) to an imiquimod-induced psoriasis model mouse. The vertical axis shows the erythema score, scale score, and skin thickness (μm), respectively. [Diagram 25] FIG. 25 shows an HE stained image of dorsal skin tissue (left) and a graph of epidermal thickness (right) on day 4 after the start of imiquimod application in an experiment of prophylactic administration of an anti-mouse CD96 neutralizing antibody (TX111.2) to an imiquimod-induced psoriasis model mouse. [Figure 26] FIG. 26 is a schematic diagram showing the protocol for an experiment of therapeutic administration of an anti-mouse CD96 neutralizing antibody (TX111.2) to a mouse model of imiquimod-induced psoriasis. [Figure 27] FIG. 27 shows photographs of the backs of a control antibody (cIg)-administered group and a TX111.2-administered group, taken 6 days after the start of imiquimod application, in an experiment of therapeutic administration of an anti-mouse CD96 neutralizing antibody (TX111.2) to an imiquimod-induced psoriasis model mouse. [Figure 28] 28 is a graph showing erythema, scale, and skin thickness of the back skin on day 1 (D1) and day 6 (D6) after the start of imiquimod application in an experiment of therapeutic administration of anti-mouse CD96 neutralizing antibody (TX111.2) to an imiquimod-induced psoriasis model mouse. The vertical axis shows the erythema score, scale score, and skin thickness (μm), respectively. [Figure 29] FIG. 29 shows an HE stained image of dorsal skin tissue (left) and a graph of epidermal thickness (right) on day 6 after the start of imiquimod application in an experiment of therapeutic administration of an anti-mouse CD96 neutralizing antibody (TX111.2) to an imiquimod-induced psoriasis model mouse. [Diagram 30] FIG. 30 is a schematic diagram showing the protocol for an experiment in which an anti-mouse CD96 neutralizing antibody (TX111.2) was administered to EAE model mice. [Diagram 31] FIG. 31 is a graph showing the time course of EAE pathology scores in an experiment in which an anti-mouse CD96 neutralizing antibody (TX111.2) was administered to EAE model mice. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] The present invention is broadly divided into five aspects. The first embodiment is an agent for suppressing the immune response of IL-17-producing cells, comprising a substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111.
[0015] A second aspect is a pharmaceutical for treating or preventing a disease or pathology involving the immune response of IL-17-producing cells, comprising the immune response suppressor of IL-17-producing cells of the first aspect.
[0016] The third embodiment is a method comprising the step (A) of culturing at least one of γδ T cells and CD4-positive T cells together with IL-23, an anti-CD3 antibody capable of stimulating the TCR / CD3 complex, and an anti-CD96 antibody capable of stimulating CD96.
[0017] The fourth aspect is a method for evaluating a pharmaceutical agent (candidate substance) for treating or preventing a disease or pathology involving the immune response of IL-17-producing cells, comprising the method of the third aspect. The fifth aspect is a method for producing IL-17, comprising the step (A) of culturing at least one of γδ T cells and CD4-positive T cells together with IL-23, an anti-CD3 antibody capable of stimulating the TCR / CD3 complex, and an anti-CD96 antibody capable of stimulating CD96.
[0018] Next, the present invention will be described in detail. <Substance that inhibits binding of CD96 to at least one protein selected from CD155 and CD111> As described later in the Examples, the present inventors have demonstrated that IL-17 production by γδ T cells is increased by CD96 activating γδ T cells. Therefore, it is presumed that inhibition of CD96 signaling suppresses activation of γδ T cells and suppresses IL-17 production by γδ T cells. In other words, a substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111 can be used as an immune response suppressor for IL-17-producing cells.
[0019] The substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111 may be used alone or in combination of two or more.
[0020] The CD96, CD155 and CD111 of the present invention include those derived from mammals such as mice, rats, hamsters, guinea pigs, dogs, pigs, and primates including monkeys and humans. The CD96, CD155 and CD111 of the present invention are preferably human CD96, CD155 and CD111.
[0021] Examples of substances that inhibit the binding of CD96 to at least one protein selected from CD155 and CD111 include substances that specifically bind to CD96, CD96 expression inhibitors, substances that specifically bind to CD155, CD155 expression inhibitors, substances that specifically bind to CD111, CD111 expression inhibitors, etc. Because they can efficiently suppress the immune response of IL-17-producing cells, substances that specifically bind to CD96, CD155, or CD111 are preferred, and substances that specifically bind to CD96 are more preferred.
[0022] The substance that specifically binds to CD96, CD155, or CD111 is not particularly limited as long as it is a substance that can inhibit the binding of CD96 to at least one protein selected from CD155 and CD111, and examples thereof include an antibody, antibody fragment, or aptamer that is anti-CD96 (anti-CD96 antibody, anti-CD96 antibody fragment, or CD96 aptamer), an antibody, antibody fragment, or aptamer that is anti-CD155 (anti-CD155 antibody, anti-CD155 antibody fragment, or CD155 aptamer), or an antibody, antibody fragment, or aptamer that is anti-CD111 (anti-CD111 antibody, anti-CD111 antibody fragment, or CD111 aptamer). The antibody may be produced by immunizing an animal such as a mouse, or may be produced by screening an antibody library such as a phage library. The antibody fragment may be an antibody fragment that contains the antibody binding site of an antibody, and may be F(ab') 2Examples of the aptamer include nucleic acid aptamers, peptide aptamers, etc. As the substance that specifically binds to CD96, CD155, or CD111, anti-CD96 antibody, anti-CD155 antibody, anti-CD111 antibody, and fragments thereof are preferred, and anti-CD96 antibody and fragments thereof are more preferred, since they can efficiently suppress the immune response of IL-17-producing cells.
[0023] The substance that specifically binds to CD96 may be solubilized CD155 or solubilized CD111. Examples of solubilized CD155 include fusion proteins of CD155 and an antibody constant region. Examples of solubilized CD111 include fusion proteins of CD111 and an antibody constant region. The substance that specifically binds to CD155 or CD111 may be solubilized CD96. Examples of solubilized CD96 include fusion proteins of CD96 and an antibody constant region.
[0024] The CD96 expression inhibitor, CD155 expression inhibitor, and CD111 expression inhibitor are not particularly limited as long as they reduce the expression of CD96, CD155, or CD111, and as a result, can inhibit the binding of CD96 to CD155 or CD111, and examples thereof include siRNA, shRNA, miRNA, ribozyme, antisense nucleic acid, and low molecular weight compounds. siRNA, shRNA, miRNA, ribozyme, and antisense nucleic acid may contain various chemical modifications to improve stability and activity. For example, in order to prevent degradation by hydrolases such as nucleases, phosphate residues may be replaced with chemically modified phosphate residues such as phosphorothioate, methylphosphonate, and phosphorodithioate. At least a part of them may be composed of a nucleic acid analog such as peptide nucleic acid (PNA).
[0025] <Anti-CD96 related molecule antibody> Anti-CD96 antibodies, anti-CD155 antibodies and anti-CD111 antibodies (hereinafter also referred to as anti-CD96-related molecule antibodies) can be produced by known antibody or antiserum production methods using full-length proteins or partial proteins of CD96, CD155 and CD111 (hereinafter also referred to as CD96-related molecules) as antigens. Since anti-CD96-related molecule antibodies desirably bind to portions expressed on the cell surface, the partial proteins are desirably the extracellular regions of CD96-related molecules. These antigens can be prepared by known protein expression and purification methods.
[0026] The anti-CD96-related molecule antibody may be either a polyclonal antibody or a monoclonal antibody. Monoclonal antibodies are preferred because it is easy to maintain a constant titer. The anti-CD96-related molecule antibody may be any of mouse antibodies, rat antibodies, guinea pig antibodies, hamster antibodies, rabbit antibodies, monkey antibodies, dog antibodies, chimeric antibodies, humanized antibodies, and human antibodies. The anti-CD96-related molecule antibody may also be chemically modified to improve physical properties such as blood retention.
[0027] The anti-CD96-related molecule antibody may have a modified constant region (Fc region). The constant region (Fc region) generally exerts effector functions such as ADCC (antibody-dependent cellular cytotoxicity) and complement-dependent cytotoxicity (CDC activity) through interaction with an Fc receptor or a complement component. It is known that the effector function is greatly influenced by the structure of complex sugar chains present in the Fc region of an antibody and genetic polymorphism of the Fc receptor. It is preferable that the anti-CD96-related molecule antibody is modified so that it does not exert effector function by introducing a mutation into the Fc region. The Fc region can be modified according to a known method.
[0028] The isotype of the anti-CD96-related molecule antibody is not particularly limited, and may be any of IgG, IgM, IgA, IgD, IgE, and the like.
[0029] The anti-CD96-related molecule antibodies may be used alone or in combination of two or more.
[0030] Antigens suitable for producing anti-CD96-related molecule antibodies include, for example, cells in which CD96-related molecules are forcibly expressed by an expression vector, CD96-related molecule expression plasmid vectors, CD96-related molecule expression virus vectors (such as adenovirus vectors), and CD96-related molecule recombinant proteins produced using such vectors. The CD96-related molecule recombinant protein may be fused with other proteins or may be tagged. From the viewpoint of protein stability, it is preferable to fuse the CD96-related molecule recombinant protein with IgGFc or the like to form a chimeric protein. The antigens used for producing anti-CD96-related molecule antibodies may be used alone or in combination of two or more. For example, when producing anti-CD96 antibodies, it is preferable to use a combination of cells in which CD96 is forcibly expressed and CD96 recombinant protein, since this allows for efficient production of highly specific antibodies.
[0031] Polyclonal antibodies can be prepared by known methods. For example, an appropriate animal is immunized with an antigen protein or a mixture of an antigen protein and a carrier protein, and an antibody-containing substance against the antigen protein is collected from the immunized animal, and the antibody is separated and purified as necessary. Examples of animals that can be used include mice, rats, sheep, goats, rabbits, and guinea pigs. In order to enhance the antibody production ability, complete Freund's adjuvant or incomplete Freund's adjuvant can be administered together with the antigen protein. Administration is generally performed once about every two weeks, about 3 to 10 times in total. Polyclonal antibodies can be collected from the blood, ascites, etc. of animals immunized by the above method. The polyclonal antibody titer in the antiserum can be measured by ELISA. Polyclonal antibodies can be separated and purified according to methods for separating and purifying immunoglobulins, such as purification methods using an antigen-binding solid phase or an active adsorbent such as protein A or protein G, salting out, alcohol precipitation, isoelectric precipitation, electrophoresis, adsorption / desorption using an ion exchanger, ultracentrifugation, and gel filtration.
[0032] Monoclonal antibodies can be prepared by known methods. Specifically, an antigen is injected subcutaneously, intramuscularly, intravenously, into the footpad, or intraperitoneally once or several times into a mammal, preferably a mouse, rat, hamster, guinea pig, or rabbit, together with a Freund's adjuvant as necessary, to immunize the mammal. Usually, immunization is performed 2 to 5 times at approximately one-month intervals from the first immunization, and antibody-producing cells can be obtained from the immunized mammal about 3 to 4 days after the final immunization. The number of immunizations and the time interval may be appropriately changed depending on the properties of the immunogen used, etc.
[0033] A hybridoma secreting a monoclonal antibody can be prepared according to the method of Kohler and Milstein et al. (Nature, 1975, vol. 256, p. 495-497) or a method based thereon. That is, a hybridoma can be prepared by fusing antibody-producing cells contained in the spleen, lymph nodes, bone marrow, tonsils, etc., obtained from an immunized mammal as described above, preferably the spleen, with myeloma cells, preferably derived from a mammal such as a mouse, rat, guinea pig, hamster, rabbit, or human, more preferably from a mouse, rat, or human, that are not capable of producing autoantibodies.
[0034] Myeloma cells used in cell fusion include established cell lines obtained from mice, such as P3-U1, NS-1, SP2, 653, X63, and AP-1.
[0035] Screening of hybridoma clones producing monoclonal antibodies is carried out by culturing hybridomas, for example, in a microtiter plate, measuring the reactivity of the culture supernatant of wells in which growth is observed against the antigen used in the above-mentioned mouse immunization by a measurement method such as RIA, ELISA, FACS, etc., and selecting clones producing monoclonal antibodies that show specific binding to the antigen or hapten. Usually, a method is used in which the antigen is immobilized and the antibody in the culture supernatant that binds to the antigen is detected with a secondary antibody labeled with a radioactive substance, a fluorescent substance, an enzyme, etc. In addition, when antigen-expressing cells are used, the hybridoma culture supernatant is added to the cells, and then a fluorescently labeled secondary antibody is reacted therewith, and the fluorescence intensity of the cells is measured with a fluorescence detection device such as a flow cytometer, thereby detecting monoclonal antibodies that can bind to the antigen of the present invention on the cell membrane.
[0036] The production of monoclonal antibodies from selected hybridoma clones can be carried out by culturing the hybridomas in vitro or in ascites fluid of mice, rats, guinea pigs, hamsters, rabbits, etc., preferably mice or rats, more preferably mice, and isolating the antibodies from the resulting culture supernatant or mammalian ascites fluid. When culturing in vitro, any nutrient medium used for growing, maintaining and storing hybridomas and producing monoclonal antibodies in the culture supernatant or any nutrient medium derived from a known basal medium can be used, depending on various conditions such as the characteristics of the cell type to be cultured, the purpose of the research and experiment, and the culture method.
[0037] The monoclonal antibodies can be isolated and purified by subjecting the above-mentioned culture supernatant or ascites fluid to saturated ammonium sulfate, ion exchange chromatography (DEAE or DE52, etc.), affinity chromatography using an anti-immunoglobulin column or protein A column, etc.
[0038] As an anti-CD96-related molecule antibody, a recombinant antibody may be used which is produced by cloning an antibody gene from an antibody-producing cell, such as a hybridoma, incorporating it into an appropriate vector, introducing this into a host, and using gene recombination technology.
[0039] Specifically, mRNA encoding the variable region of an antibody is isolated from a hybridoma producing the antibody of interest or an immune cell producing the antibody, such as a sensitized lymphocyte, immortalized with an oncogene or the like. For the isolation of mRNA, total RNA is prepared by a known method, such as guanidine ultracentrifugation, and mRNA is prepared using an mRNA Purification Kit (Pharmacia), or the like. cDNA of the antibody variable region is synthesized from the obtained mRNA using reverse transcriptase. cDNA synthesis can be performed using an AMV Reverse Transcriptase First-strand cDNA Synthesis Kit, or the like. In addition, the 5'-RACE method using 5'-Ampli FINDER RACE Kit (Clontech) and PCR can be used to synthesize and amplify cDNA. The desired DNA fragment is purified from the obtained PCR product and linked to vector DNA. Furthermore, a recombinant vector is prepared from this, and introduced into E. coli or the like to select colonies to prepare the desired recombinant vector. The base sequence of the desired DNA is confirmed by a known method, such as the deoxygenation method.
[0040] Once the DNA encoding the variable region of the antibody of interest is obtained, it can be ligated to DNA encoding the desired antibody constant region and incorporated into an expression vector. Alternatively, the DNA encoding the variable region of the antibody can be incorporated into an expression vector containing DNA of the antibody constant region. To produce the antibody of interest, the antibody gene is incorporated into an expression vector so that it is expressed under the control of an expression control region, for example, an enhancer / promoter. Next, the host cell can be transformed with this expression vector to express the antibody.
[0041] For expression of the antibody genes, the heavy and light chains of the antibody may be separately incorporated into expression vectors and cotransformed into the host, or DNAs encoding the heavy and light chains may be incorporated into a single expression vector and transformed into the host.
[0042] The antibody may be produced by the so-called phage display method (Nature Biotechnology 23, 1105 (2005)). Specifically, an antibody gene library produced by a known method using B lymphocytes of humans or animals (e.g., rabbits, mice, rats, hamsters, etc.) as a material, or an antibody gene library completely synthesized by selecting and modifying germ line sequences of humans or animals, is displayed on the cell surface of bacteriophage, E. coli, yeast, animal cells, etc., or on ribosomes. Examples of the form of the antibody displayed on the cell surface include IgG molecules, IgM molecules, Fab fragments, single chain Fv (scFv) fragments, etc.
[0043] The antibody fragment gene thus obtained can be recombined with the corresponding region of an IgG antibody gene by known methods to obtain an antibody gene. The gene thus obtained can then be inserted into an appropriate vector, which can then be introduced into a host to produce an antibody using gene recombination techniques.
[0044] <Substances specifically binding to CD96> CD96 is a transmembrane protein that exists in two isoforms in humans. Isoform 1 has been detected in acute myeloid leukemia and contains additional amino acids compared to isoform 2. In humans, isoform 2 is the more common form, and the predicted domain structure of isoform 2 has three external immunoglobulin-like domains (domains 1, 2, and 3). Mouse CD96 exists as a single isoform and has three external immunoglobulin-like domains (domains 1, 2, and 3).
[0045] A substance that specifically binds to CD96 preferably binds to at least one of the CD96 isoforms. A substance that specifically binds to human CD96 preferably binds to CD96 isoform 2.
[0046] A specific binding agent for CD96 preferably binds to the amino acid sequence of at least one extracellular immunoglobulin-like domain of CD96. A specific binding agent for CD96 may bind to the amino acid sequence of domain 1; domain 2; domain 3; domain 1 and domain 2; domain 1 and domain 3; domain 2 and domain 3; or domain 1, domain 2, and domain 3, but preferably binds to domain 1. A specific binding agent for CD96 may bind to other CD96 domains or amino acid sequences in addition to the at least one extracellular immunoglobulin-like domain.
[0047] A specific binding agent for CD96 inhibits, blocks or antagonizes the binding of CD96 to CD 155. A specific binding agent for CD96 preferably inhibits or blocks at least partially the binding of CD96 to CD155 by binding to the extracellular domain of CD96 or a portion thereof capable of interacting with CD155.
[0048] The specific binding agent for CD96 preferably inhibits or reduces CD96 signaling. The inhibition or reduction of CD96 signaling may be by inhibiting, blocking or antagonizing binding to CD155, or by blocking CD96-induced signaling that would normally occur in response to CD155 binding. By way of example, CD96 contains an immunoreceptor tyrosine-based inhibitory motif (ITIM). The specific binding agent for CD96 may have the ability to inhibit or reduce CD96 signaling mediated by the ITIM of CD96.
[0049] <Anti-CD96 antibody> The anti-CD96 antibody is not particularly limited as long as it has specificity for CD96. A commercially available or known anti-CD96 antibody may be used, or TX111.2 disclosed in the present specification may be used, or the antibody may be newly prepared by various known methods, with TX111.2 being preferred.
[0050] Examples of commercially available anti-CD96 antibodies include mouse anti-human CD96 monoclonal antibody (clone: NK92.39, No. 338402) manufactured by Biolegend, mouse anti-human CD96 monoclonal antibody (clone: NK92.50.1, No. sc-53574 and clone: NK92.39.1, No. sc-53575) manufactured by Santa Cruz, sheep anti-human CD96 polyclonal antibody (No. AF6199) manufactured by RSD, etc. Furthermore, examples of commercially available anti-CD96 antibodies include the four commercially available anti-human CD96 antibodies (1C8, NK92.39, 3H8, MAA6359) described in Japanese Patent No. 6618908.
[0051] Other known anti-CD96 antibodies include, for example, those described in Japanese Patent No. 6618908. The method of obtaining the anti-CD96 antibodies can be as follows: 4 CD96 knockout mice are immunized with mouse CD96 ectodomain protein, and 4 CD96 knockout mice are immunized with purified human CD96 ectodomain protein. Immunizations are performed approximately three times at 4-week intervals. Mice are bled 10-12 days after the third immunization, and the serum is titrated for antigen screening by ELISA. The mouse with the highest antibody titer is used for fusion. Alternatively, if the mouse does not respond adequately, further immunizations are attempted. After cloning the selected hybridomas and purifying mAbs (monoclonal antibodies) from each clone, the individual human or mouse mAbs are screened using screening assays to identify anti-CD96 antibodies (CD96 binding assay to CD155, ADCC assay, and assay of human leukocyte effector function modulation by human CD96 antibodies), or assay of mouse NK cell function modulation by anti-CD96 antibodies, respectively. Optionally, clones are isotyped to identify antibodies that are less likely or unable to induce ADCC, such as IgG2 and IgG4 antibodies.
[0052] Further examples of other known anti-CD96 antibodies are the anti-human CD96 mouse monoclonal antibodies m1718, m1719, m1720, m1721, and m1722 described in WO 2019 / 091449, and chimeric and humanized antibodies derived therefrom.
[0053] As the anti-CD96 antibody, a commercially available or known anti-CD96 antibody mutant, chimeric antibody, humanized antibody, or the like may be used.
[0054] Among the anti-CD96 antibodies having specificity against CD96, those that inhibit or reduce CD96 signaling, that is, anti-CD96 neutralizing antibodies, are preferred.
[0055] The anti-CD96 neutralizing antibody is not particularly limited, but preferred examples include mouse anti-human CD96 monoclonal antibody (clone: NK92.39, No. 338402) manufactured by Biolegend and TX111.2 disclosed herein.
[0056] The anti-CD96 neutralizing antibody comprises a light chain variable region comprising the following amino acid sequence: the amino acid sequence of SEQ ID NO: 14 as CDR1, the amino acid sequence of SEQ ID NO: 15 as CDR2, and the amino acid sequence of SEQ ID NO: 16 as CDR3, and A heavy chain variable region comprising the following amino acid sequence: CDR1 is the amino acid sequence of SEQ ID NO: 17, CDR2 is the amino acid sequence of SEQ ID NO: 18, and CDR3 is the amino acid sequence of SEQ ID NO: 19 It is preferable that the antibody has the following structure:
[0057] The anti-CD96 neutralizing antibody is preferably an antibody having a light chain variable region having the amino acid sequence of SEQ ID NO:12 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:13.
[0058] The anti-CD96 neutralizing antibody is preferably an antibody having a light chain variable region having an amino acid sequence at least 90% identical to SEQ ID NO:12 and a heavy chain variable region having an amino acid sequence at least 90% identical to SEQ ID NO:13.
[0059] The anti-CD96 neutralizing antibody is preferably an antibody having a light chain variable region having an amino acid sequence of SEQ ID NO: 12 in which one or several amino acids have been substituted, added, or deleted in a region other than CDR1 to CDR3, and which is at least 90% identical to SEQ ID NO: 12, and a light chain variable region / heavy chain variable region having an amino acid sequence of SEQ ID NO: 13 in which one or several amino acids have been substituted, added, or deleted in a region other than CDR1 to CDR3, and which is at least 90% identical to SEQ ID NO: 13.
[0060] <IL-17> IL-17 (Interleukin-17) refers to the IL-17 family, including IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. When evaluating IL-17, it is sufficient to evaluate at least one of the members of the IL-17 family. IL-17 is preferably IL-17A, since it is produced in large amounts and is easy to measure.
[0061] IL-17-producing cells The IL-17-producing cells are not particularly limited as long as they are cells that produce IL-17, and examples of such cells include γδT cells, Th17 cells, and ILC3 cells.
[0062] γδ T cells are cells that have a T cell receptor consisting of γ and δ chains on the cell surface and produce IL-17. Th17 cells (type 17 helper T cells) are a subset of helper T cells (Th cells) and are cells that produce IL-17. In other words, Th17 cells can be said to be CD4+ T cells (CD4 positive T cells) that produce IL-17.
[0063] ILC3 cells are group 3 innate lymphoid cells (ILC) that require the transcription factor RORγt and produce IL-17. ILC3 cells include lymphoid tissue inducer (LTi) and ILC22 cells that produce IL-22.
[0064] IL-17-producing cells, particularly γδ T cells, Th17 cells, and ILC3 cells, can also produce IL-22. IL-17-producing cells are preferably γδ T cells because of their significant involvement in diseases or pathological conditions.
[0065] <Immune response inhibitor of IL-17-producing cells> The immune response of IL-17-producing cells refers to the reaction that occurs in IL-17-producing cells among the reactions that are specifically responsive to eliminate foreign substances, whether exogenous or endogenous, and can be either innate immunity or acquired immunity. The immune response of IL-17-producing cells is, for example, cytokine production, including the production of IL-17, IL-22, TNF, IFN-γ, etc.
[0066] The immune response of IL-17-producing cells may also be an induced immune response by a reaction that mimics the reaction specifically responsive to eliminate foreign substances, whether exogenous or endogenous. For example, when it is known that cytokines are produced by cells that recognize foreign substances, the immune response of IL-17-producing cells induced by the addition of such cytokines in an in vitro test system is also included in the immune response of IL-17-producing cells. The method for inducing the immune response of IL-17-producing cells is not particularly limited, but induction by cytokines is preferred, and induction by IL-23 is more preferred.
[0067] The immune response inhibitor of IL-17-producing cells may suppress cytokine production, but it only needs to have the effect of suppressing any of the various immune responses in IL-17-producing cells induced by the produced cytokines.
[0068] The immune response suppressor of IL-17-producing cells is preferably a cytokine production suppressor, and more preferably an IL-17 production suppressor or an IL-22 production suppressor. The use of the immune response suppressor of IL-17-producing cells is not particularly limited, but it is preferably used for treating or preventing a disease or pathology in which the immune response of IL-17-producing cells is involved. The disease or pathology in which the immune response of IL-17-producing cells is involved is not particularly limited as long as it is a disease or pathology in which the immune response of IL-17-producing cells is involved, and is preferably psoriasis, rheumatoid arthritis, atopic dermatitis, multiple sclerosis, cerebral infarction, nephritis, lung injury, pulmonary fibrosis, or skin tumor, more preferably psoriasis or multiple sclerosis, and even more preferably psoriasis.
[0069] Treating or preventing a disease or condition includes, for example, inhibiting the onset of the disease or condition, inhibiting the progression of the disease or condition, and reducing or alleviating the symptoms of the disease or condition.
[0070] Psoriasis includes psoriasis vulgaris, psoriasis arthropica, pustular psoriasis, guttate psoriasis, erythrodermic psoriasis, etc. Psoriasis is usually diagnosed by keratotic erythema accompanied by thick silvery white scales, and pathologically, by the presence of acanthosis with extended psoriasis-like epidermal projections, parakeratosis with loss of the granular layer, and substratum corneum neutrophilic microabscesses.
[0071] Multiple sclerosis includes relapsing-remitting MS, primary progressive MS (PPMS), secondary progressive MS (SPMS), and progressive relapsing MS (PRMS). Multiple sclerosis can be diagnosed when a patient develops a single demyelinating symptom called CIS (Clinically Isolated Syndrome), and the demyelinating symptoms are temporally or spatially multiple. The immune response suppressor of IL-17-producing cells of the present invention can also be effective for use in preventing or suppressing the progression of CIS to multiple sclerosis.
[0072] The dosage (effective amount) of the immune response suppressor of IL-17-producing cells is not particularly limited, and may be appropriately selected depending on the type of disease or pathology involving the immune response of IL-17-producing cells, the severity of symptoms, the recipient (age, sex, weight, etc.), the administration route, etc. For example, when the substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111 is an anti-CD96 antibody, the immune response suppressor of IL-17-producing cells containing 0.5 to 50 mg, preferably 0.7 mg to 10 mg, more preferably 1 mg to 5 mg of anti-CD96 antibody per kg body weight in one administration may be administered once to several times a day. The total number of administrations and the frequency of administration are also not particularly limited, and may be appropriately selected depending on the type of disease or pathology involving the immune response of IL-17-producing cells, the severity of symptoms, the recipient (age, sex, weight, etc.), the administration route, etc., and may be administered only once, may be administered continuously every day, or may be administered over one to several weeks with an interval of several days.
[0073] The immune response inhibitor of IL-17-producing cells may be administered to a living body as it is, but it is preferable to administer it as a pharmaceutical product in which an effective amount of the immune response inhibitor of IL-17-producing cells is formulated with a pharma- ceutical acceptable carrier. The method of administration is not particularly limited, and may be oral or parenteral. The method of administration is preferably parenteral, more preferably intraperitoneal injection or intravenous injection.
[0074] <Drugs for treating or preventing diseases or pathologies involving the immune response of IL-17-producing cells> The pharmaceutical product of the present invention for treating or preventing a disease or pathology involving the immune response of IL-17-producing cells is not particularly limited as long as it contains the immune response inhibitor of IL-17-producing cells, and may contain a pharma- ceutical acceptable carrier in addition to the immune response inhibitor of IL-17-producing cells.
[0075] The disease or pathological condition involving an immune response of IL-17-producing cells is not particularly limited as long as it involves an immune response of IL-17-producing cells, but is preferably psoriasis, rheumatoid arthritis, atopic dermatitis, multiple sclerosis, cerebral infarction, nephritis, lung injury, pulmonary fibrosis or skin tumor, more preferably psoriasis or multiple sclerosis, and even more preferably psoriasis.
[0076] The form of the pharmaceutical is not particularly limited, and may be, for example, an injection, an infusion, an oral preparation (tablet, granule, powder, capsule (including soft capsule), solution, suspension), or an external preparation (for example, lotion, emulsion, patch, or ointment). The pharmaceutical may be prepared in the form of a freeze-dried preparation or an aqueous solution.
[0077] The dosage of the pharmaceutical agent is not particularly limited and may be appropriately selected depending on the type of disease or pathological condition and the severity of the symptoms in which the immune response of IL-17-producing cells is involved. The pharma- ceutically acceptable carrier may be, but is not limited to, a buffer such as phosphate, citrate, and other organic acids; an antioxidant such as ascorbic acid and methionine; a preservative such as octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, benzyl alcohol, alkyl parabens, catechol, resorcinol, cyclohexanol, 3-pentanol, m-cresol; a low molecular weight polypeptide; serum albumin, gelatin, or immunoglobulin. Examples of such surfactants include proteins such as purine; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; sugars such as glucose, mannose, sucrose, mannitol, trehalose, sorbitol, and dextrin; chelating agents such as EDTA; salt-forming counterions such as sodium; metal complexes; polyhydric alcohols such as polyethylene glycol (PEG), and non-ionic surfactants such as polysorbate 20 and polysorbate 80.
[0078] The subject to which the pharmaceutical agent is administered is not particularly limited, but is preferably a mammal, more preferably a human.
[0079] One embodiment of the present invention is a method for suppressing the immune response of IL-17-producing cells, comprising administering to a subject an effective amount of a substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111. Furthermore, one embodiment of the present invention is a method for treating or preventing a disease or pathology involving the immune response of IL-17-producing cells, comprising administering to a subject an effective amount of a substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111. Furthermore, one embodiment of the present invention is a method for treating or preventing psoriasis, rheumatoid arthritis, atopic dermatitis, multiple sclerosis, cerebral infarction, nephritis, lung injury, pulmonary fibrosis or skin tumors, comprising administering to a subject an effective amount of a substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111.
[0080] One embodiment of the present invention is a substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111, for use in suppressing the immune response of IL-17-producing cells. Furthermore, one embodiment of the present invention is a substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111, for treating or preventing a disease or pathological condition involving the immune response of IL-17-producing cells. Furthermore, one embodiment of the present invention is a substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111 for treating or preventing psoriasis, rheumatoid arthritis, atopic dermatitis, multiple sclerosis, cerebral infarction, nephritis, lung injury, pulmonary fibrosis or skin tumors.
[0081] <Method Having Step (A)> A third aspect of the present invention is a method comprising the step (A), in which step (A) is a step of culturing at least one of γδ T cells and CD4-positive T cells together with IL-23, an anti-CD3 antibody capable of stimulating the TCR / CD3 complex, and an anti-CD96 antibody capable of stimulating CD96.
[0082] The method having step (A) of the present invention can be said to be a method for treating at least one of γδ T cells and CD4 positive T cells. The purpose and use of the method having step (A) are not particularly limited, but in the method, an immune response is induced in γδ T cells or CD4 positive T cells by stimulating at least one of γδ T cells and CD4 positive T cells with IL-23, an anti-CD3 antibody capable of stimulating the TCR / CD3 complex, and an anti-CD96 antibody capable of stimulating CD96, and therefore the method can be used, for example, to elucidate the immune response mechanism in γδ T cells or CD4 positive T cells, and to screen and evaluate pharmaceuticals that have the effect of inhibiting, suppressing, promoting, or enhancing the immune response in γδ T cells or CD4 positive T cells.
[0083] One embodiment of the present invention is a cell culture method comprising the step (A) of culturing at least one of γδ T cells and CD4-positive T cells together with IL-23, an anti-CD3 antibody capable of stimulating the TCR / CD3 complex, and an anti-CD96 antibody capable of stimulating CD96. Furthermore, step (A) makes it possible to induce an immune response in γδ T cells or CD4-positive T cells, to activate γδ T cells or CD4-positive T cells, and to induce IL-17 production in γδ T cells or CD4-positive T cells. Therefore, step (A) can also be used as a method for inducing an immune response in γδ T cells or CD4 positive T cells, a method for activating γδ T cells or CD4 positive T cells, or a method for inducing IL-17 production in γδ T cells or CD4 positive T cells. In the method for inducing an immune response in γδ T cells or CD4 positive T cells, for example, as described below, the presence or absence of induction of an immune response can be evaluated using as an indicator the production of cytokines such as IL-17, IL-22, TNF, and IFN-γ. In the method for activating γδ T cells or CD4 positive T cells, for example, the presence or absence of activation can be evaluated using activation markers such as CD69 and CD25 as indicators, as described below. In the method for inducing IL-17 production in γδ T cells or CD4 positive T cells, for example, the presence or absence of induction of IL-17 production can be evaluated using the amount of IL-17 produced, IL-17 activity, or the like as an index, as described below.
[0084] IL-23 is a cytokine that is produced by antigen-presenting cells and is known to induce an immune response of γδ T cells. In addition, IL-23R and IL-12Rβ1 are known as receptors for IL-23. In the method having step (A), IL-23 is added to induce an immune response of γδ T cells or CD4 positive T cells. As IL-23, any origin is acceptable as long as it is an IL-23 protein, and a protein purified from a living body may be used, or a recombinant protein derived from E. coli, yeast, plant cells, mammalian cells, or insect cells may be used. As long as it can induce an immune response of γδ T cells or CD4 positive T cells, IL-23 may be full length or a part of it, and there are no limitations on the presence or absence of post-translational modification, glycosylation, carrier, etc. Since it can efficiently induce an immune response of γδ T cells or CD4 positive T cells, IL-23 is preferably a recombinant protein, and more preferably a recombinant protein derived from mammalian cells or insect cells.
[0085] The final concentration of IL-23 in the culture system is preferably 0.001 to 20 ng / ml, and more preferably 0.01 to 1 ng / ml.
[0086] An anti-CD3 antibody capable of stimulating the TCR / CD3 complex is used to stimulate the TCR / CD3 complex on the surface of a T cell. The anti-CD3 antibody capable of stimulating the TCR / CD3 complex is not particularly limited as long as it can stimulate the TCR / CD3 complex on the surface of a T cell, and examples of such an anti-CD3 antibody include a solid-phased anti-CD3 antibody and an agonistic (stimulatory) anti-CD3 antibody. Since it is easily available, a solid-phased anti-CD3 antibody is preferred. When a solid-phased anti-CD3 antibody is added to a cell, CD3 is cross-linked by the antibody, and a signal from CD3 enters, resulting in a signal similar to the signal of antigen recognition by TCR being transmitted into the T cell.
[0087] By immobilizing the anti-CD3 antibody, it becomes an anti-CD3 antibody capable of stimulating the TCR / CD3 complex. Therefore, the anti-CD3 antibody used for immobilization is not particularly limited as long as it can specifically bind to the TCR / CD3 complex on the surface of T cells, and various anti-CD3 antibodies such as NO. 40-0031 manufactured by TONBO can be used. Depending on the animal species from which the γδ T cells are derived, an anti-CD3 antibody that binds to the TCR / CD3 complex of that animal species can be selected.
[0088] The concentration of the anti-CD3 antibody used for immobilization is preferably 1 ng / ml to 10 μg / ml, and more preferably 10 ng / ml to 1 μg / ml.
[0089] An anti-CD96 antibody capable of stimulating CD96 is used to stimulate CD96 on the surface of T cells. The anti-CD96 antibody capable of stimulating CD96 is not particularly limited as long as it can stimulate CD96 on the surface of T cells, and examples of such antibodies include solid-phased anti-CD96 antibodies and agonistic (stimulatory) anti-CD96 antibodies. Solid-phased anti-CD96 antibodies are preferred because they are easily available. When solid-phased anti-CD96 antibodies are added to cells, CD96 is cross-linked by the antibody, and a signal from CD96 enters, resulting in a signal being transmitted into the T cells similar to that when CD155 on the cell surface, which is a natural ligand, binds to CD96.
[0090] By immobilizing an anti-CD96 antibody, it becomes an anti-CD96 antibody capable of stimulating CD96. Therefore, the anti-CD96 antibody used for immobilization is not particularly limited as long as it can specifically bind to CD96 on the cell surface, and various anti-CD96 antibodies can be used. For example, eBioscience TM Examples include rat anti-mouse CD96 antibody (Invitrogen, No. 16-0960-82), anti-human CD96 antibody (clone: NK92.39, Biolegend, No. 338402), TX111.2, etc. Depending on the animal species from which γδ T cells are derived, an anti-CD96 antibody that binds to CD96 of that animal species may be selected.
[0091] The concentration of the anti-CD96 antibody used for immobilization is preferably 100 ng / ml to 1 mg / ml, and more preferably 1 μg / ml to 200 μg / ml.
[0092] The solid phase for immobilizing the anti-CD3 antibody or anti-CD96 antibody is not particularly limited, and may be, for example, a plate, a dish, a bag, a membrane, beads, etc. Since immobilization is easy, a plate is preferable, and a plate having a plurality of wells is more preferable. The material of the solid phase is not particularly limited, and glass, polystyrene, etc. can be suitably used. Since immobilization can be efficiently performed and it is easy to obtain, the solid phase for immobilizing the anti-CD3 antibody or anti-CD96 antibody is preferably a polystyrene plate.
[0093] The solid phase surface may be untreated or may be treated to make it hydrophobic or hydrophilic. 2 A functional group such as a >NH group may be introduced.
[0094] The method for immobilizing anti-CD3 antibody or anti-CD96 antibody is not particularly limited, and various known methods can be used. For example, the antibody can be immobilized on the solid phase using electrostatic interaction, hydrophobic interaction (physical adsorption), hydrogen bond, charge transfer, covalent bond, etc., but hydrophobic interaction is preferable because of its simple operation. Immobilization using hydrophobic interaction can be performed, for example, by adding an antibody solution to a plate, incubating for a certain period of time, discarding the antibody solution, and washing. The antibody solution should be used in an amount sufficient to cover the surface of the solid phase. For example, when the solid phase is a 96-well plate, it is preferable to add 50 to 200 μl / well.
[0095] The method having step (A) may optionally include step (D) of evaluating an immune response in γδ T cells or CD4 positive T cells after carrying out step (A). The immune response in γδ T cells or CD4 positive T cells means a reaction that occurs in γδ T cells or CD4 positive T cells among reactions that are carried out in a specific response to eliminate exogenous or endogenous foreign substances, and may be a reaction due to natural immunity or acquired immunity. The immune response in γδ T cells or CD4 positive T cells is, for example, cytokine production, such as production of IL-17, IL-22, TNF, IFN-γ, etc., with IL-17 production being preferred. That is, the method having step (A) preferably includes step (B) of evaluating IL-17 after carrying out step (A).
[0096] The method having step (A) may be carried out in vivo or in vitro, preferably in vitro.
[0097] <Process (B)> Step (B) is an optional step that may be performed after step (A), and is a step of evaluating IL-17. By evaluating IL-17, the status of γδ T cells or CD4-positive T cells, in particular the immune response, can be evaluated.
[0098] Thus, one example embodiment of the present invention is Step (A): Culturing at least one of γδ T cells and CD4 positive T cells with IL-23, an anti-CD3 antibody capable of stimulating the TCR / CD3 complex, and an anti-CD96 antibody capable of stimulating CD96; and Step (B): Evaluating IL-17 derived from at least one of the γδ T cells and the CD4-positive T cells subjected to step (A). It is a method having the following structure. The above-mentioned method makes it possible to evaluate the immune response of γδ T cells or CD4-positive T cells, and to evaluate the activation of γδ T cells or CD4-positive T cells. Therefore, the method can be used as a method for evaluating the immune response of γδ T cells or CD4-positive T cells, and as a method for evaluating the activation of γδ T cells or CD4-positive T cells.
[0099] The method for evaluating IL-17 is not particularly limited as long as it can evaluate IL-17, and examples thereof include a method for measuring the amount of IL-17 produced and a method for measuring the activity of IL-17. The evaluation of IL-17 may be performed by evaluating IL-17 derived from the cells subjected to step (A), and may include evaluating intracellular IL-17 or, for example, evaluating IL-17 released outside the cells, which is present in the cell culture supernatant. The method for evaluating IL-17 is preferably a method for measuring the amount of IL-17 produced, since many associations with diseases have been reported. Examples of the measurement of the amount of IL-17 produced include measurement of the amount of IL-17 mRNA by quantitative PCR, measurement of the amount of IL-17 protein by Western blotting or ELISA, and measurement of the amount of intracellular IL-17 protein by a flow cytometer. Since the measurement can capture changes upstream of IL-17 production, the method is preferably measurement of the amount of IL-17 mRNA by quantitative PCR. As primers for measuring the amount of IL-17 mRNA by quantitative PCR, it is preferable to use Forward: 5'-TTTAACTCCCTTGGCGCAAAA-3' (SEQ ID NO: 1) and Reverse: 5'-CTTTCCCTCCGCATTGACAC-3' (SEQ ID NO: 2).
[0100] <Drug evaluation methods> The fourth aspect of the present invention, the method for evaluating a pharmaceutical product (candidate substance), is a method for evaluating a pharmaceutical product (candidate substance) for treating or preventing a disease or pathology involving the immune response of IL-17-producing cells, including a method having step (B) after step (A). The method for evaluating a pharmaceutical product (candidate substance) of the present invention makes it possible to evaluate the effect of a pharmaceutical product (candidate substance) to inhibit, suppress, promote, or enhance the immune response of IL-17-producing cells. The method for evaluating a pharmaceutical product (candidate substance) of the present invention has a step (C) of adding a pharmaceutical product (candidate substance) to γδ T cells or CD4 positive T cells. The order of step (C) is usually before step (A), simultaneously with step (A), or after step (A) and before step (B).
[0101] Thus, one example embodiment of the present invention comprises: Step (A): Culturing at least one of γδ T cells and CD4-positive T cells together with IL-23, an anti-CD3 antibody capable of stimulating the TCR / CD3 complex, and an anti-CD96 antibody capable of stimulating CD96; Step (B): Evaluating IL-17 derived from at least one of the γδ T cells and the CD4 positive T cells subjected to step (A); and Step (C): adding a drug candidate substance to the γδ T cells or the CD4 + T cells before, simultaneously with, or after step (A) and before step (B). The present invention relates to a method for evaluating a drug candidate substance for treating or preventing a disease or pathology involving the immune response of IL-17-producing cells.
[0102] The pharmaceutical evaluation method of the present invention performs steps (A) and (B) in the presence and absence of a candidate substance, and when the amount of IL-17 produced in the presence of the candidate substance is less than the amount of IL-17 produced in the absence of the candidate substance, the candidate substance can be determined to be effective for treating or preventing a disease or pathology involving the immune response of IL-17-producing cells.
[0103] The method of evaluating a pharmaceutical (candidate substance) of the present invention may be a method of screening a pharmaceutical (candidate substance).
[0104] Thus, one example embodiment of the present invention comprises: Step (A): Culturing at least one of γδ T cells and CD4-positive T cells together with IL-23, an anti-CD3 antibody capable of stimulating the TCR / CD3 complex, and an anti-CD96 antibody capable of stimulating CD96; Step (B): Evaluating IL-17 derived from at least one of the γδ T cells and the CD4 positive T cells subjected to step (A); and Step (C): adding a drug candidate substance to the γδ T cells or the CD4 + T cells before, simultaneously with, or after step (A) and before step (B). The present invention relates to a method for screening for a drug candidate substance for treating or preventing a disease or pathology involving the immune response of IL-17-producing cells.
[0105] The screening method of the pharmaceutical (candidate substance) of the present invention is to perform step (A) and step (B) in the presence and absence of the pharmaceutical (candidate substance). When the amount of IL-17 production in the presence of the pharmaceutical (candidate substance) is less than the amount of IL-17 production in the absence of the pharmaceutical (candidate substance), the pharmaceutical (candidate substance) can be selected as a candidate for a pharmaceutical for treating or preventing a disease or condition in which the immune response of IL-17-producing cells is involved. For example, when the amount of IL-17 production in the presence of the pharmaceutical (candidate substance) is 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 80% or less of the amount of IL-17 production in the absence of the pharmaceutical (candidate substance), the pharmaceutical (candidate substance) can be selected as a candidate for a pharmaceutical for treating or preventing a disease or condition in which the immune response of IL-17-producing cells is involved. When the amount of IL-17 production in the presence of the pharmaceutical (candidate substance) is 10%, 20%, 30%, 40%, or 50% or less of the amount of IL-17 production in the absence of the pharmaceutical (candidate substance), it is preferable to select the pharmaceutical (candidate substance) as a candidate for a pharmaceutical for treating or preventing a disease or condition in which the immune response of IL-17-producing cells is involved.
[0106] Examples of the pharmaceutical (candidate substance) include, but are not particularly limited to, low molecular weight compounds, proteins, polypeptides, polysaccharides, nucleic acids, etc. The pharmaceutical (candidate substance) may be a novel substance or a known substance.
[0107] The disease or condition in which the immune response of the IL-17-producing cells is involved is preferably psoriasis, rheumatoid arthritis, atopic dermatitis, multiple sclerosis, cerebral infarction, nephritis, lung injury, pulmonary fibrosis, or skin tumor, and more preferably psoriasis.
[0108] <IL-17 production method> The IL-17 production method according to the fifth aspect of the present invention comprises the step (A) of culturing at least one of γδ T cells and CD4 positive T cells with IL-23, an anti-CD3 antibody capable of stimulating the TCR / CD3 complex, and an anti-CD96 antibody capable of stimulating CD96. By stimulating the γδ T cells or CD4 positive T cells with IL-23, an anti-CD3 antibody capable of stimulating the TCR / CD3 complex, and an anti-CD96 antibody capable of stimulating CD96, IL-17 production is induced in the γδ T cells or CD4 positive T cells. The IL-17 production method, which is the fifth aspect of the present invention, can also be said to be a method for producing IL-17, which comprises the step (A) of culturing at least one of γδ T cells and CD4 positive T cells together with IL-23, an anti-CD3 antibody capable of stimulating the TCR / CD3 complex, and an anti-CD96 antibody capable of stimulating CD96.
[0109] The use of IL-17 obtained by the above-mentioned method for producing IL-17 is not particularly limited, and it may be used after isolation by affinity chromatography, immunoprecipitation, etc. Furthermore, the γδ T cells or CD4 positive T cells in which IL-17 is produced may be used for screening and evaluation of pharmaceuticals that have the effect of inhibiting, suppressing, promoting, or enhancing IL-17 production.
[0110] The method for producing IL-17 may be carried out in vivo or in vitro, but is preferably carried out in vitro. EXAMPLES
[0111] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to these. Example 1 ≪Method≫ Imiquimod-induced psoriasis model In this model, inflammation is induced by applying imiquimod (IMQ) to the shaved back skin of mice for 3-6 consecutive days, and it is widely used as a pathological model of psoriasis. Pathological conditions characteristic of psoriasis, such as epidermal thickening, parakeratosis, and infiltration of neutrophils and monocytes into the dermis, are observed, and the mechanism has been reported to be as follows: IMQ activates dendritic cells via TLR7, resulting in the production of IL-23. IL-23 activates γδT cells via IL-23R / IL-12Rβ1 on γδT cells, resulting in the production of IL-17 and IL-22. IL-17 and IL-22 promote the migration of neutrophils to the affected area, inducing erythema, scaling, and skin thickening.
[0112] Mice were 6-8 week-old males of C57BL / 6J (wild type mice) and CD96-deficient mice, divided into 4 mice for the imiquimod group (IMQ) and naive group. CD96-deficient mice were generated by genome editing technology (CRISPR / Cas9). AATAGAGACAAATCGGACTCTGG (SEQ ID NO: 3) was used as the target sequence. The backs of the mice were shaved, and the imiquimod group was applied with 5% imiquimod cream (Veselna Cream, Mochida Pharmaceutical Co., Ltd.) at 31.25 mg / time / mouse once a day. The naive group was applied with Vaseline instead of 5% imiquimod cream. The first day of application of imiquimod cream or Vaseline was set as day 0, and the cream was applied on days 0, 1, and 2, and analysis was performed on day 3.
[0113] (Erythema and scale evaluation) The erythema and scales on the back were scored based on the Psoriasis Area and Severity Index (PASI), which is used to diagnose psoriasis in humans, and were rated on a 5-point scale: 0: none, 1: mild, 2: moderate, 3: severe, and 4: extremely severe.
[0114] (Skin Thickness Assessment) The skin on the back of the mouse was lifted and the thickness was measured using a dial thickness gauge type G (manufactured by Ozaki Manufacturing Co., Ltd.), and the measured value was divided by 2 to obtain the skin thickness (μm). Measurements were taken at three locations per mouse, and the average value was calculated. Errors were calculated using the values for each mouse, and then a significant difference test was performed for each group.
[0115] (Preparation and observation of tissue specimens) Three days after the start of application, the skin on the back of the mouse was collected, fixed in formalin, and embedded in paraffin. 10 μm-thick tissue sections were prepared and stained with HE (hematoxylin, eosin) to prepare tissue specimens. The tissue specimens were observed and photographed using a microscope (BZ-X710, Keyence Corporation). The epidermal thickness on the images was measured and recorded as the epidermal thickness (μm). Three specimens were prepared per mouse, and the thickness was measured at five points per specimen, and the average value was calculated. Errors were calculated using the values for each mouse, and then a significant difference test was performed for each group.
[0116] (Skin neutrophil count) On the third day after the start of application, 2 cm of the skin on the back of the mouse was 2 The skin cells were harvested and separated using 1 mg / ml collagenase IV (Sigma-Aldrich). Viable cells were counted using a ViaCount assay (GE Healthcare). Skin cells were stained with Brilliant Violet421-rat anti-mouse CD45.2 antibody (Biolegend), APC / Cy7-rat anti-mouse / human CD11b antibody (Biolegend), and Alexa Fluor 700-rat anti-mouse Ly6G antibody (BD Biosciences), and cells stained with all three antibodies were counted as neutrophils. Analysis was performed using a flow cytometer (LSR Fortessa TM The number of neutrophils was divided by the area of the collected skin to obtain the number of neutrophils in the skin.
[0117] (IL-23 production from skin-derived myeloid cells) On the third day after the start of application, 2 cm of the skin on the back of the mouse was 2 The skin cells were harvested and separated using 1 mg / ml collagenase IV (Sigma-Aldrich). Live cells were counted using a ViaCount assay (GE Healthcare). Skin cells were stained with Brilliant Violet421-rat anti-mouse CD45.2 antibody (Biolegend) and APC / Cy7-rat anti-mouse / human CD11b antibody (Biolegend), and cells stained with both antibodies were identified as myeloid cells and sorted using a cell sorter (FACSAria). TM The samples were sorted using a 100% PBS (manufactured by Becton Dickinson Japan).
[0118] These cells were harvested, and mRNA was extracted using ISOGEN (Nippon Gene Co., Ltd.) according to the product protocol. cDNA was synthesized from mRNA using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the protocol. Quantitative PCR was performed using SYBR Green PCR Master Mix (Invitrogen), and analysis was performed using ABI 7500 fast (Applied Biosystems) to measure the expression level of IL-23. The primers used for IL-23 were Forward: 5'-CAGCTCTCTCGGAATCTCTGC-3' (SEQ ID NO: 4), Reverse: 5'-GACCTTGGCGGATCCTTTGC-3' (SEQ ID NO: 5).
[0119] (IL-23 receptor expression level on skin-derived gamma delta T cells) On the third day after the start of application, 2 cm of the skin on the back of the mouse was 2The skin cells were isolated using 1 mg / ml collagenase IV (Sigma-Aldrich). Viable cells were counted using the ViaCount assay (GE Healthcare). The skin cells were incubated with Brilliant Violet421-rat anti-mouse CD45.2 antibody (Biolegend) and eBioscience TM The cells were stained with FITC-hamster anti-mouse TCR GAMMA DELTA antibody (Catalog No. 118106, Biolegend), and cells stained with both antibodies were sorted as γδ T cells using a cell sorter (FACSAria, Becton Dickinson Japan).
[0120] The mRNA extraction, cDNA synthesis, and quantitative PCR were performed as described above, and the production amounts of IL-23R and IL-12Rβ1 were measured. The primers used for IL-23R were Forward: 5'-GCAACATGACATGCACCTGG-3' (SEQ ID NO: 6), Reverse: 5'-GACAGCTTGGACCCATACCA-3' (SEQ ID NO: 7). The primers used for IL-12Rβ1 were Forward: 5'-ATGGCTGCTGCGTTGAGAA-3' (SEQ ID NO: 8), Reverse: 5'-AGCACTCATAGTCTGTCTTGGA-3' (SEQ ID NO: 9).
[0121] (IL-17 and IL-22 production by mouse skin-derived γδ T cells) Preparation of γδT cells, mRNA extraction, cDNA synthesis, and quantitative PCR were performed as described above, and the amounts of IL-17 and IL-22 produced were measured. The IL-17 primers used were the same as described above. The IL-22 primers used were Forward: 5'-TTTCCTGACCAAACTCAGCA-3' (SEQ ID NO: 10) and Reverse: 5'-CTGGATGTTCTGGTCGTCAC-3' (SEQ ID NO: 11).
[0122] (Percentage of IL-17 positive cells in mouse skin-derived γδ T cells) On the third day after the start of application, 2 cm of the skin on the back of the mouse was 2 The skin cells were isolated using 1 mg / ml collagenase IV (Sigma-Aldrich), and the viable cells were counted using a ViaCount assay (GE Healthcare).
[0123] The harvested cells were analyzed using GolgiStop TM The medium was incubated at 37°C in 5% CO in RPMI-1640 medium (R-8758, Sigma-Aldrich) containing 1:2000 BD Biosciences RPMI-1640 and 5% FBS. 2 The cells were cultured for 2 hours under the same conditions. Brilliant Violet421-rat anti-mouse CD45.2 antibody (Biolegend), eBioscience TM After staining with FITC-hamster anti-mouse TCR GAMMA DELTA antibody (Catalog No. 118106, Biolegend), eBioscience TM After fixing with Foxp3 / Transcription Factor Fixation / Permeabilization Concentrate and Diluent (Invitrogen), IL-17 produced by γδ T cells was stained with PE-rat anti-mouse IL17A antibody (BD Biosciences). Analysis was performed using a flow cytometer (LSR Fortessa TM Cells stained with PE-rat anti-mouse IL17A antibody were considered IL-17 positive, and the percentage of IL-17 positive cells was calculated by dividing the number of γδ T cells.
[0124] IL-17 production in mouse spleen-derived γδ T cells stimulated with IL-23 and CD96 Spleens were collected from wild-type mice (C57BL / 6, 6-8 week-old males, obtained from Japan Claire), and crushed using a slide glass to separate cells. Viable cells were counted using the ViaCount assay (GE Healthcare). Spleen cells were incubated with Brilliant Violet421-rat anti-mouse CD45.2 antibody (Biolegend) and eBioscience TM The cells were stained with FITC-hamster anti-mouse TCR GAMMA DELTA antibody (Invitrogen, Catalog No. 11-5811-82), and cells stained with both antibodies were sorted as γδ T cells using a cell sorter (FACSAria, Becton Dickinson Japan).
[0125] First, the antibody was immobilized on a plate. Specifically, the antibody was immobilized on a 96-well plate (Corning, No. 3596) using eBioscience TM Rat anti-mouse CD96 antibody (Invitrogen, No. 16-0960-82, 20 μg / ml) or rat IgG2a (BD Bioscience, No. 554687, 20 μg / ml, also known as rG2a) as a control was added at 100 μL / well and incubated at 37°C for 2 hours, after which the antibody solution was discarded and the plate was washed once with PBS.
[0126] γδT cells were seeded on this plate at 15,000 cells / well, and recombinant mouse IL-23 (R&D systems, No. 1887-ML-010, final concentration 0.1 ng / ml) was added to RPMI-1640 medium (Sigma-Aldrich, R-8758) supplemented with 10% FBS and recombinant mouse IL-2 (BD Bioscience, No. 55069, final concentration 2 ng / ml). The cells were incubated at 37°C, 5% CO 2 The cells were incubated for 18 hours under ambient conditions. The mRNA extraction, cDNA synthesis, and quantitative PCR were performed as described above to measure the amount of IL-17 produced. The IL-17 primers used were the same as those described above.
[0127] IL-17 production in mouse spleen-derived γδ T cells stimulated with IL-23, CD96, and CD3 The same method as described above for "IL-17 production in mouse spleen-derived γδ T cells stimulated with IL-23 and CD96" was used, and in the group where the CD3 signal was added, anti-CD3 antibody (Tonbo, No. 40-0031, final concentration 0.1 μg / ml) was immobilized on the plate. Immobilization was performed in the same manner as for anti-CD96 antibody.
[0128] (Activation of mouse spleen-derived γδ T cells) The method was the same as that described above in "Activation of IL-17-producing γδ T cells in spleen-derived γδ T cells by stimulation with IL-23, CD96, and CD3." Activation of γδ T cells was evaluated using CD69 and CD25 as activation markers. γδ T cells were stained with APC-hamster anti-mouse CD69 antibody (Biolegend) and PE-rat anti-mouse CD25 antibody (Biolegend), and analyzed using a flow cytometer (LSR Fortessa TM (manufactured by Becton Dickinson Japan Co., Ltd.) was used.
[0129] (human PBMC-derived γδ T cells) In accordance with the Declaration of Helsinki, written informed consent was obtained from the subjects prior to the study. This study was also approved by the Ethics Committee of the University of Tsukuba Medical School. The subjects were healthy volunteers. 60 ml of blood was collected from the subjects, and peripheral blood mononuclear cells (PBMCs) were isolated using Lymphoprep (Stemcell technologies, NO. 07801). Viable cells were counted using a ViaCount assay (GE Healthcare). Vδ2 γδ T cells in PBMCs were stained with PE-anti-hTCRγδ (eBiosciences, NO. 12-9959-42) and BV605-anti-hVδ2 (BD Biosciences, NO. 743751), sorted using a cell sorter (FACSAria, Becton Dickinson Japan), and used as human PBMC-derived γδ T cells for the experiment.
[0130] (Human PBMC-derived CD4+ T cells) Ten milliliters of blood was collected from healthy volunteers, and peripheral blood mononuclear cells (PBMCs) were isolated using Lymphoprep (Stemcell Technologies, No. 07801). Viable cells were counted using a ViaCount assay (GE Healthcare). Human CD4 microbeads (Miltenyl Biotec, No. 130-045-101) were used to isolate human PBMC-derived CD4+ T cells for the experiment.
[0131] Expression of CD96 on human PBMC-derived γδ T cells and CD4+ T cells Human PBMC-derived γδ T cells were incubated with PE-anti-hCD96 (Biolegend, No. 338406) or PE-mouse IgG1 isotype control (BD Biosciences, No. 555749), and then analyzed by flow cytometer. Human PBMC-derived CD4+ T cells were also analyzed in the same manner.
[0132] IL-17 production in human PBMC-derived γδ T cells Human PBMC-derived γδ T cells were seeded on plates immobilized with anti-CD3 and CD96 antibodies, stimulated for 48 hours, and then IL-17 production by γδ T cells was evaluated. Immobilization of the antibodies was performed according to the above-mentioned "IL-17 production in spleen-derived γδ T cells stimulated with IL-23 and CD96". The antibodies used for immobilization were 100ng / ml Anti-hCD3 (BD Biosciences, No. 555336) and 20μg / ml Anti-hCD96 (Biolegend, No. 338404). γδT cells were seeded at 250,000 cells / well and incubated in RPMI-1640 medium (Sigma-Aldrich, R-8758) containing 10% FBS and Recombinant Human TGF-beta 1 (R&D Systems, NO. 240-B, final concentration 50 ng / ml), Recombinant Human IL-1β (R&D Systems, NO. 201-LB, final concentration 10 ng / ml), Recombinant Human IL-23 (R&D Systems, NO. 1290-IL, final concentration 20 ng / ml), Recombinant Human IL-6 (R&D Systems, NO. 7270-IL, final concentration 50 ng / ml), Recombinant Human IL-12 (BD Pharmingen, 100 mg / mL), and 100 mg / mL of 100% FBS. TM , No. 554613, final concentration 10 ng / ml) was added and incubated at 37°C, 5% CO 2 The cells were cultured under ambient conditions for 48 hours. IL-17A protein in the cell culture supernatant was measured using the Human IL-17A Flex set (BD Biosciences, No. 560383).
[0133] Activation of human PBMC-derived γδ T cells and human PBMC-derived CD4+ T cells A T cell enriched fraction containing γδ T cells and CD4+ T cells was seeded on a plate immobilized with anti-CD3 and CD96 antibodies, and after stimulation for 18 hours, activation of γδ T cells and CD4+ T cells was evaluated using CD69 and CD25 as activation markers. Immobilization of antibodies was performed according to the above-mentioned "IL-17 production in spleen-derived γδ T cells stimulated with IL-23 and CD96". The antibodies used for immobilization were 100ng / ml Anti-hCD3 (BD Biosciences, No. 555336) and 20μg / ml Anti-hCD96 (Biolegend, No. 338404). Specifically, biotin-anti-hCD14 (Biolegend, No. 301826) and biotin-anti-hCD19 (BD Biosciences, No. 555411) were bound to PBMCs, and cells expressing neither CD14 nor CD19 were negatively selected using streptavidin Microbeads (Miltenyl Biotec, No. 130-048-102) to enrich for T cells. This T cell enriched fraction was seeded at 500,000 cells / well on a plate immobilized with anti-CD3 and CD96 antibodies, and incubated at 37°C in 5% CO in 10% FBS, RPMI-1640 medium (Sigma-Aldrich, No. R-8758). 2 The cells were incubated for 18 hours under ambient conditions. After culturing, the cells were analyzed using a flow cytometer. γδ T cells were stained with PE-anti-hTCRγδ (BD Biosciences, No. 555717), and CD4+ T cells were stained with V500-anti-hCD4 (BD Biosciences, No. 560768), and activation markers were detected in each cell. FITC-anti-hCD69 (BD Biosciences, No. 555530) and PE-Cy7-anti-hCD25 (TONBO, 60-0259-T025) were used as activation markers.
[0134] IL-17 production in human PBMC-derived CD4+ T cells Instead of human PBMC-derived γδ T cells, human PBMC-derived CD4+ T cells were used, and the same procedure as described above for “IL-17 production in human PBMC-derived γδ T cells” was followed. Note that the stimulation time after seeding human PBMC-derived CD4+ T cells on a plate immobilized with anti-CD3 and CD96 antibodies was 96 hours.
[0135] Effect of anti-CD96 neutralizing antibody on IL-17 production by human PBMC-derived CD4+ T cells Human PBMC-derived CD4+ T cells premixed with anti-CD96 neutralizing antibodies were seeded onto plates immobilized with anti-CD3 antibodies and hCD155-Fc (a chimeric protein of CD155, the natural ligand of CD96, and Fc), and stimulated for 6 hours, after which IL-17 production by the CD4+ T cells was evaluated. The pMX plasmid, which contained the full-length human CD155 gene integrated into the N-terminus of the human IgGFc gene, was transfected into 293gp cells to obtain a chimeric protein (hCD155-Fc) in which the full-length human CD155 gene was fused with human IgGFc. hCD155-Fc was purified using protein-A agarose and then used in the following experiments. DOTAP (1,2-dioleoyl-3-trimethylammoniumpropane, monochloride, Cayman, NO.15110) was added to a 96-well plate (Corning, NO.3596) at a final concentration of 1 mg / ml, and after leaving it for 15 minutes, the solution was discarded and the plate was washed twice with PBS. 100ng / ml Anti-hCD3 (BD Biosciences, NO.555336) and 10μg / ml hCD155-Fc were added to this plate at 100μL / well, and then incubated overnight at 4℃, after which the solution was discarded and the plate was washed once with PBS to immobilize the anti-CD3 antibody and hCD155-Fc. DOTAP is a cationic lipid, and was used to firmly stand the antibody and Fc protein on the plate and efficiently introduce stimulation. CD155 was used as a chimeric protein with Fc, CD155-Fc, in order to efficiently immobilize CD155 on the plate. Immobilized hCD155-Fc can stimulate CD96 in vitro. Anti-human CD96 neutralizing antibody (clone: NK92.39, Biolegend, No. 338402) was added to CD4+ T cells derived from human PBMCs from healthy individuals at 10 μg / 2 × 10 5 The CD4+ T cells were added to the 1000 cells, and anti-human CD96 antibody was allowed to bind to the CD96 of the CD4+ T cells. As a control, CD4+ T cells were added with PBS instead of the anti-human CD96 neutralizing antibody. CD4+ T cells premixed with anti-human CD96 neutralizing antibody were seeded onto a plate immobilized with anti-CD3 antibody and hCD155-Fc, and the cells were cultured for 6 hours as described above in “IL-17 production in human PBMC-derived γδ T cells.” IL-17A protein in the cell culture supernatant was measured using the Human IL-17A Flex set (BD Biosciences, No. 560383).
[0136] Establishment of anti-CD96 neutralizing antibody, TX111.2 The pMX plasmid containing the mouse CD96 cDNA was cotransfected with a retrovirus envelope vector (VSV-G) into 293gp cells to obtain a recombinant retrovirus. This virus was then transduced into mouse lymphoma cell line BW5147.3 (hereafter referred to as BW cells) to obtain a mouse CD96 stable expressing cell line (hereafter referred to as CD96-BW cells) that strongly expresses the full-length mouse CD96. The pMX plasmid, in which the mouse CD96 gene was integrated into the N-terminus of the human IgGFc gene, was transfected into 293gp cells to obtain a chimeric protein (mCD96-huIgGFc) in which the full-length mouse CD96 protein was fused with human IgGFc. mCD96-huIgGFc was purified using protein-A agarose and then used for immunization. CD96-deficient mice were inoculated with a CD96-BW cell suspension (5 × 10 7 1×10 cells / mL in PBS 7 The mice were intraperitoneally injected with mCD96-humanIgGFc (10 μg in PBS) one time. One month later, mCD96-humanIgGFc was intraperitoneally injected five times in total at monthly intervals. Three days after the final immunization, splenocytes were collected from the immunized mice. The splenocytes were fused with mouse myeloma cell line SP2 / 0-Ag14 using polyethylene glycol to produce hybridomas. Hybridomas producing antibodies that specifically recognize mCD96 were screened by FACS using CD96-BW cells. The antibody produced by the obtained clone was designated TX111. The DNA sequences of the variable regions of the light and heavy chains of TX111 were determined by PCR as described in Thomas Tiller et al., Journal of immunological methods, 350, 2009, 183-193. CDRs (complementarity determining regions) 1 to 3 of the variable regions of the light chain and heavy chain of TX111 were determined using IgBLAST. From the hybridoma producing TX111, mRNA encoding the variable regions of the heavy and light chains of the antibody was extracted. cDNAs of the variable regions of the heavy and light chains of the antibody were synthesized from the obtained mRNA using reverse transcriptase. The two cDNAs were combined into pCDNA with a mutated Fc inserted so that the Fc region would not bind to the Fc receptor. TM The two vectors were then transfected into 293F cells using ExpiFectamine. TM Transfection was performed using 293 Transfection Kit (Thermos Fisher, No. A14525). The antibody purified from the culture supernatant using HiTrap Protein G (Merck, No. GE17-0404-01) was named TX111.2.
[0137] Binding specificity of anti-mouse CD96 neutralizing antibody TX111.2 CD96-BW cells 1 x 10 5 10ng of TX111.2 or 10ng of Mouse IgG2b isotypic control (TONBO, No. 70-4732-U100) was added to the cells and incubated on ice for 30 minutes. After washing with PBS, APC-anti-mIgG (Biolegend, No. 405308) was added and incubated on ice for 20 minutes, stained, and analyzed by flow cytometer. Competitive inhibition between anti-mouse CD96 neutralizing antibody TX111.2 and CD155 The pMX plasmid, which contained the full-length mouse CD155 gene integrated into the N-terminus of the human IgGFc gene, was transfected into 293gp cells to obtain a chimeric protein (mCD155-huIgGFc) in which the full-length mouse CD155 gene was fused with human IgGFc. mCD155-huIgGFc was purified using protein-A agarose and then used in the following experiments. CD96-BW cells (TF) 1×10 5 1 μg of mCD155-huIgGFc was added to the cells and incubated on ice for 30 minutes. After washing with PBS, 1000 ng, 100 ng, 10 ng, 1 ng, or 0.1 ng of TX111.2 was added. After incubation at room temperature for 30 minutes, PE-anti-huIgG (Biolegend, NO. 410708) was added, incubated on ice for 20 minutes, stained, and analyzed by flow cytometer. CD155-huIgGFc is a chimeric protein in which mouse CD155 and human IgG Fc are fused.
[0138] <An experiment using anti-mouse CD96 neutralizing antibody prophylactically administered to imiquimod-induced psoriasis model mice> The backs of C57BL / 6J mice (wild type, 8 weeks old, male) were shaved and 5% imiquimod cream (Veselna Cream, Mochida Pharmaceutical Co., Ltd.) was applied once a day at 62.5 mg / mouse. Vaseline was applied instead of 5% imiquimod cream to the naive group. The first day of application of imiquimod cream was set as day 0, and it was applied on days 0, 1, 2, and 3, and analysis was performed on days 3 and 4. The TX111.2 administration group (N=5) was intravenously injected with 100 μg of anti-mouse CD96 neutralizing antibody TX111.2 on the day before the first day of application of imiquimod cream (day -1). The group administered 100 μg of mouse IgG (cIg) instead of TX111.2 was used as the control antibody administration group (N=5). Mouse IgG was produced in 293F cells and purified from the culture supernatant using HiTrap Protein G (Merck, No. GE17-0404-01). On the third day after application of imiquimod, the skin on the back of the mice was photographed. On the fourth day after application of imiquimod, erythema, scale, and skin thickness were evaluated, and skin tissue specimens were prepared. The skin tissue specimens were observed, and the epidermal thickness was measured.
[0139] <Therapeutic administration of anti-mouse CD96 neutralizing antibody to imiquimod-induced psoriasis model mice> The backs of C57BL / 6J mice (wild type, 8 weeks old, male) were shaved and 5% imiquimod cream (Veselna Cream, Mochida Pharmaceutical Co., Ltd.) was applied once a day at 62.5 mg / mouse. Vaseline was applied instead of 5% imiquimod cream to the naive group. The first day of application of imiquimod cream was set as day 0, and the cream was applied on days 0, 1, 2, 3, 4, and 5, and analysis was performed on days 1 and 6. The TX111.2-administered group (N=6) was intraperitoneally injected with 100 μg of anti-mouse CD96 neutralizing antibody TX111.2 on day 1 of application of imiquimod cream. The group administered 100 μg of mouse IgG (cIg) instead of TX111.2 was used as the control antibody-administered group (N=6). On the sixth day after application of imiquimod, the skin on the back of the mice was photographed. In addition, erythema, scale, and skin thickness were evaluated on the first and sixth days after application of imiquimod. Skin tissue specimens were prepared on the sixth day after application of imiquimod. The skin tissue specimens were observed, and the epidermal thickness was measured.
[0140] <EAE model> Experimental autoimmune encephalomyelitis (EAE) is an inflammatory demyelinating disease of the central nervous system. EAE is an autoimmune model in which experimental animals are inoculated with encephalitogenic proteins (peptides), such as proteins or peptides derived from the central nervous tissue of other animals, to induce myelin protein-specific T cells and develop autoimmune encephalomyelitis. Demyelination is induced by injecting encephalitogenic proteins (peptides) emulsified with an adjuvant such as Freund's complete adjuvant. The presence of the adjuvant induces an inflammatory response to these encephalitogenic proteins (peptides). In many experimental methods, the encephalitogenic proteins (peptides) are injectable with pertussis toxin (PTX) at the same time as the injectable proteins to disrupt the blood-brain barrier and allow immune cells to enter the central nervous system. This injectable causes multiple, scattered small demyelinated areas to develop in the brain and spinal cord, resulting in a series of symptoms. EAE shares many common pathologies with multiple sclerosis (MS) and acute disseminated encephalomyelitis, and is therefore widely used in research into the pathology and treatment of these diseases. EAE is also a model for T cell-mediated autoimmune diseases in general.
[0141] <Anti-mouse CD96 neutralizing antibody administration experiment to EAE model mice> The EAE model was developed using C57BL / 6J mice (wild type, 11 weeks old, female) transfected with Hookie kit MOG. 35-55EAE was induced and generated using PTX / CFA Emulsion (Hooke laboratories, EK-2110) according to the protocol attached to the product. Myelin Oligodendrocyte Glycolipid (MOG) was used as the encephalitis-inducing peptide. MOG / CFA (Complete Friends' Adjuvant) was administered subcutaneously at 0.1 mL each at two sites (total 0.2 mL / mouse). Then, PTX was administered intraperitoneally at 0.1 mL / mouse (day 0). The next day (day 1), PTX was administered intraperitoneally again at 0.1 mL / mouse. The TX111.2 administration group (N=5) was intraperitoneally injected with 100 μg of anti-mouse CD96 neutralizing antibody TX111.2 on the day before the start of MOG / CFA and PTX administration (day -1). After the start of MOG / CFA and PTX administration, 100 μg of TX111.2 was intraperitoneally administered twice a week for a total of 10 times. The group administered 100 μg of mouse IgG (cIg) instead of TX111.2 was used as the control antibody administration group (N = 5).
[0142] The EAE pathology score was evaluated every day after EAE induction according to the protocol provided with the product, using a scale of 0 to 5 in 0.5 increments as shown below, where 0 indicates no abnormality and the higher the number, the more severe the symptoms.
[0143] 0: No obvious changes in motor function compared to non-immunized mice. When lifted by the base of the tail, the tail is firm and upright. Hind limbs are normally spread apart. There is no walking or head tilt when the mouse is walking.
[0144] 0.5: The tip of the tail is drooping. When you lift the base of the tail, you can feel tension everywhere except at the tip. Muscle tension can be felt as the tail continues to move.
[0145] 1.0: Tail is drooping. When lifted by the base, the tail is not upright but hangs entirely over the fingers. Hind legs are normally spread apart. No signs of tail movement are observed.
[0146] 1.5: Tail and hind limb movement is impaired. When the base of the tail is lifted, the entire tail hangs down over the finger. When the mouse is dropped onto a wire rack, at least one hind limb consistently passes through the wire. Gait is very slightly unsteady.
[0147] 2.0:A or B. A: Tail drooping and weakness in hind limbs. When lifted by the base of the tail, the legs are not spread apart and are close together. When the mouse is observed walking, there is a noticeable unsteady gait. One leg may drag on the toes, but the other leg is not obviously hindered. B: The mouse appears to have a score of 0.0, but when observed gait there is clear evidence of head tilt. Poor balance.
[0148] 2.5:A, B or C. A: Tail droop and dragging of hind legs. Both hind legs have some movement, but both are dragging (stumbling on their hind legs). B: No movement in one leg, or complete limp in one leg, but movement in the other leg. C: When the mouse was grasped, the severity of EAE appeared to be mild (score 0.0-1.5), but there was significant head tilt and the mouse occasionally fell over.
[0149] 3.0: A, B, C or D. A: Tail droop and complete paralysis of the hind legs (most common). B: The tail is drooping and the hind legs are almost completely paralyzed. One or both hind legs can be flailing, but neither can move forward past the hip joint. C: The tail is drooping and one front leg and one back leg are paralyzed. D: Meet all of the following a to d. a: Violent head tilt, b: walking only along the edge of the cage, c: pushing against the cage wall, d: turning when lifted by the base of the tail.
[0150] 3.5:A or B. A: The tail is drooping and the hind legs are completely paralyzed. Moreover, the mouse moves around in the cage, but when placed on its side, it cannot return to its original position. The hind legs are on one side of the body. B: The mouse moves around in the cage, but the hindquarters of its body are flat like a pancake, and the frontquarters of the mouse's body appear humped.
[0151] 4.0: Tail drooping, complete paralysis of hind limbs and partial paralysis of forelimbs. Mice move around the cage minimally but appear awake and consume food. In most cases, after a score of 4.0 for 2 days, euthanasia is recommended. However, with daily subcutaneous injections of fluids, most C57BL / 6 mice can recover to 3.5 or 3.0. If a mouse is euthanized due to severe paralysis, it will be scored as 5.0 for the remainder of the experiment.
[0152] 4.5: Complete paralysis of hind limbs and partial paralysis of forelimbs. Immobile in cage. Mouse is not awake. Mouse has minimal movement of forelimbs. Mouse barely responds to touch. Euthanasia is recommended. If a mouse is euthanized due to severe paralysis, it should receive a score of 5.0 for the remainder of the experiment.
[0153] 5.0: A, B or C. A: Mice spontaneously roll around in their cages (euthanasia recommended). B: The mouse is found dead due to paralysis. C: Euthanized due to severe paralysis.
[0154] ≪Results≫ Imiquimod-induced psoriasis model Figure 1 shows photographs of the backs of wild-type and CD96-deficient mice in an imiquimod-induced psoriasis model taken 3 days after application. In each photograph, the mouse on the left is the naive (naive) group, and the mouse on the right is the imiquimod (IMQ) group. In wild-type mice, the imiquimod group showed skin redness and scaling compared to the naive group. In CD96-deficient mice, the imiquimod group showed skin redness and scaling compared to the naive group, but the severity was less than in wild-type mice.
[0155] Figure 2 shows a graph comparing erythema, scale, and skin thickness between wild-type and CD96-deficient mice on the third day after application. The vertical axis of the erythema and scale graphs is the erythema score and scale score, respectively, and the vertical axis of the skin thickness graph is skin thickness (μm). In the naive group, neither erythema nor scale was observed in wild-type mice nor CD96-deficient mice.
[0156] In the imiquimod group, both wild-type and CD96-deficient mice had higher erythema scores than the naive group, but the CD96-deficient mice had significantly lower erythema scores than the wild-type mice.
[0157] In the imiquimod group, both wild-type and CD96-deficient mice had higher scale scores than the naive group, but the CD96-deficient mice had significantly lower scale scores than the wild-type mice.
[0158] In the imiquimod group, both wild-type and CD96-deficient mice had thicker skin than the naive group, but the skin of the CD96-deficient mice was significantly thinner than that of the wild-type mice. These results indicate that CD96 deficiency attenuated the pathology of imiquimod-induced erythema, scaling, and skin thickening.
[0159] Figure 3 shows a photograph of HE stained tissue specimens from mouse back skin 3 days after the start of imiquimod application. In wild-type mice, pathological conditions characteristic of psoriasis, such as epidermal thickening, parakeratosis, and infiltration of neutrophils and mononuclear cells into the dermis, were observed, but these pathological conditions were attenuated in CD96-deficient mice. Figure 4 shows a graph of epidermal thickness. In wild-type mice, the epidermal thickness was about four times that of the naive group, but about twice that of the CD96-deficient mice, indicating that epidermal thickening caused by imiquimod was attenuated.
[0160] The number of neutrophils in the skin is shown in Figure 5. In wild-type mice, the number of neutrophils increased dramatically in the imiquimod group compared to the naive group, but the effect of imiquimod on increasing the number of neutrophils in the skin was weakened in CD96-deficient mice.
[0161] Next, we investigated the amount of IL-23 produced by myeloid cells (Figure 6). In both wild-type and CD96-deficient mice, the amount of IL-23 produced in the imiquimod group was dramatically increased compared to the naive group, but no significant difference was observed between wild-type and CD96-deficient mice. In other words, CD96 is not thought to be involved in the promotion of IL-23 production by imiquimod.
[0162] Furthermore, we investigated the expression levels of IL-23R and IL-12β1, which are receptors for IL-23, in γδ T cells (Figure 7). No significant differences in the expression levels of IL-23R and IL-12β1 were observed between wild-type mice and CD96-deficient mice. This suggests that CD96 is not involved in regulating the expression levels of IL-23 receptors in γδ T cells.
[0163] Next, we examined the amounts of IL-17 and IL-22 produced by γδ T cells. In wild-type mice, the imiquimod group produced dramatically more IL-17 than the naive group, but in CD96-deficient mice, there was no difference in the amount of IL-17 produced between the imiquimod group and the naive group (Figure 8, left). In other words, CD96 is thought to be involved in the promotion of IL-17 in γδ T cells by imiquimod. In both wild-type and CD96-deficient mice, the amount of IL-22 produced was increased in the imiquimod group compared to the naive group, but the increase was attenuated in the CD96-deficient mice compared to the wild-type mice (Figure 8, right). In other words, CD96 is thought to be involved in the promotion of IL-22 production in γδ T cells by imiquimod.
[0164] The percentage and number of IL-17-producing cells in γδ T cells are shown in Figure 9. In wild-type mice, the percentage of IL-17-producing cells was increased in the imiquimod group compared to the naive group, but the increase in the percentage of IL-17-producing cells by imiquimod was attenuated in CD96-deficient mice. The number of IL-17-producing cells was also increased in the imiquimod group compared to the naive group in wild-type mice, but the increase in the number of IL-17-producing cells by imiquimod was attenuated in CD96-deficient mice. In other words, CD96 is thought to be involved in the increase in IL-17-producing cells in γδ T cells by imiquimod.
[0165] These results suggest that CD96 is closely involved in the pathology of psoriasis in the imiquimod-induced psoriasis model. As for the mechanism, CD96 is not involved in the step of IL-23 production in myeloid cells such as dendritic cells or the step of IL-23 receptor production in γδT cells, but plays an important role in the step of IL-17 production by γδT cells activated by IL-23, and CD96 is thought to increase IL-17 production. Therefore, it is speculated that IL-17 production can be suppressed by inhibiting the signal of CD96, and psoriasis can be treated or prevented. Furthermore, it is speculated that diseases or pathologies involving the immune response of IL-17-producing cells other than psoriasis can also be treated or prevented by inhibiting the signal from CD96. IL-17 production in mouse spleen-derived γδ T cells
[0166] Next, we analyzed the mechanism by which CD96 increases IL-17 production in γδ T cells using spleen-derived γδ T cells from wild-type mice. Figure 10 shows a graph comparing the amount of IL-17 produced with and without the addition of IL-23. It can be seen that IL-23 increases the amount of IL-17 produced in γδ T cells. CD96 was stimulated with anti-CD96 antibody (a-CD96) immobilized on a plate, but no significant difference was observed in the amount of IL-17 produced compared to the control antibody rat IgG2a (rG2a). In other words, it was shown that CD96 does not enhance the IL-23 signal that increases IL-17 production. In vivo, CD96 is activated by recognizing CD155 on target cells, but in vitro, CD96 can be stimulated with immobilized anti-CD96 antibody.
[0167] Mechanism of IL-17 production in γδT cells It has been reported that administration of the T cell receptor (TCR) signal inhibitor AX-024 attenuates psoriasis pathology in an imiquimod-induced psoriasis model, suggesting that TCR signaling is necessary for the induction of psoriasis pathology (Science translational medicine, 2016). In other words, it is believed that not only cytokines but also T cell activation via TCR is essential for the induction of psoriasis pathology.
[0168] Therefore, we activated γδ T cells by stimulating CD3, which forms a complex with the T cell receptor, with immobilized anti-CD3 antibody, and investigated the effect of CD96 on this activation. In vivo, T cells are activated when the T cell receptor recognizes antigens presented by cells of the innate immune system (especially dendritic cells), but in vitro, T cells can be activated by stimulating CD3, which forms a complex with the T cell receptor, with immobilized anti-CD3 antibody.
[0169] As shown in FIG. 11, the amount of IL-17 production did not change with CD3 signal alone, and when IL-23 was added in addition to immobilized anti-CD3 antibody (a-CD3), IL-17 production increased significantly. Furthermore, when CD96 was stimulated with immobilized anti-CD96 antibody (a-CD96), IL-17 production increased even more. The results of investigating whether γδ T cells were activated at this time are shown in FIG. 12. The expression levels of CD69 and CD25, which are T cell activation markers, increased by CD96 stimulation using immobilized anti-CD96 antibody (a-CD96). In other words, it is considered that the IL-17 production of γδ T cells is increased by CD96 enhancing the T cell receptor signal of γδ T cells, thereby activating γδ T cells. Therefore, it is speculated that if the CD96 signal is inhibited, the T cell receptor signal of γδ T cells is not enhanced, the activation of γδ T cells is suppressed, and the IL-17 production of γδ T cells is suppressed.
[0170] Expression of CD96 on human PBMC-derived γδ T cells and CD4+ T cells The left side of Figure 13 shows that CD96 is expressed on γδ T cells derived from human PBMCs. The right side of Figure 13 shows that CD96 is also expressed on CD4+ T cells derived from human PBMCs.
[0171] IL-17 production in human PBMC-derived γδ T cells As shown in Figure 14, in γδ T cells derived from all seven subjects (Human Volunteer; HV1-7), when CD96 was stimulated with immobilized anti-CD96 antibody (a / CD96), IL-17 production was significantly increased compared to the control (mIgG1). From this result, it is considered that, as with mouse spleen-derived γδ T cells, CD96 enhances the T cell receptor signal in human PBMC-derived γδ T cells, thereby increasing IL-17 production.
[0172] Activation of human PBMC-derived γδ T cells As shown in Figure 15, in γδ T cells derived from all six subjects (HV1-6), when CD96 was stimulated with immobilized anti-CD96 antibody (a / CD96), the expression levels of T cell activation markers CD69 and CD25 increased compared to the control (mIgG1). In other words, it is considered that IL-17 production by γδ T cells is increased by CD96 enhancing the T cell receptor signal of γδ T cells, thereby activating the γδ T cells.
[0173] IL-17 production in human PBMC-derived CD4+ T cells As shown in Figure 16, when CD96 was stimulated with immobilized anti-CD96 antibody (a / CD96) in CD4+ T cells derived from all eight subjects (HV1-8), IL-17 production was significantly increased compared to the control (mIgG1). This result suggests that IL-17 production is also increased in human PBMC-derived CD4+ T cells by CD96 enhancing the T cell receptor signal.
[0174] Activation of human PBMC-derived CD4+ T cells As shown in Figure 17, when CD96 was stimulated with immobilized anti-CD96 antibody (a / CD96) in CD4+ T cells derived from all six subjects (HV1-6), the expression levels of T cell activation markers CD69 and CD25 increased compared to the control (mIgG1). In other words, it is considered that the IL-17 production of human PBMC-derived CD4+ T cells is increased by CD96 enhancing the T cell receptor signal, thereby activating the CD4+ T cells.
[0175] Effect of anti-CD96 neutralizing antibody on IL-17 production by human PBMC-derived CD4+ T cells In Fig. 18, the row "Stimulation" indicates the substances used for immobilization to stimulate CD4+T cells. The row "Blocking" indicates substances that were mixed with CD4+T cells in advance to block the binding of other molecules to CD96. When hCD155-Fc was immobilized on a plate in addition to anti-CD3 antibody (a / CD3) and CD96 was stimulated, IL-17 production in CD4+T cells was significantly increased compared to stimulation with immobilized anti-CD3 antibody alone. Furthermore, when anti-CD96 neutralizing antibody (neutral a / CD96) was mixed with CD4+T cells in advance, the binding of hCD155-Fc to CD96 was blocked, and IL-17 production in CD4+T cells was significantly suppressed compared to when PBS was mixed. In other words, anti-CD96 neutralizing antibody suppressed IL-17 production, which is one of the immune responses of human PBMC-derived CD4+T cells. These results suggest that anti-CD96 neutralizing antibodies can be used as agents to suppress the immune response of IL-17-producing cells and may be effective in preventing and treating diseases in which inflammation is caused by IL-17.
[0176] <CD96 Functions> These results indicate that CD96 functions as an activating receptor for immune responses in IL-17-producing cells, such as γδ T cells and CD4+ T cells, and that this function of CD96 in IL-17-producing cells is common to both mice and humans.
[0177] Therefore, in both mice and humans, it is speculated that inhibition of CD96 signaling would not enhance T cell receptor signaling in γδ T cells and CD4+ T cells, suppressing the activation of γδ T cells and CD4+ T cells and inhibiting IL-17 production.
[0178] The role of CD96 in the immune control system is still unclear. For example, it is known that CD96 functions as an immunosuppressive receptor in mouse NK cells. Therefore, it has been reported that anti-CD96 antibodies may be used as drugs to reduce immunosuppression, i.e., to activate immune responses. In human NK cells, CD96 was initially reported as an immune-activating receptor (Anja Fuchs et.al., J Immunol, 2004, 172, 3994-3998, Cutting Edge: CD96 (Tactile) Promotes NK Cell-Target Cell Adhesion by Interacting with the Poliovirus Receptor (CD155)). However, it is currently under debate whether CD96 functions as an activating or inhibitory receptor in human NK cells. Therefore, when targeting K cells, anti-CD96 antibodies in humans may not activate immune responses. On the other hand, the present inventors have found that CD96 in IL-17-producing cells functions as an activating receptor for immune responses in both mice and humans. In other words, since the function of CD96 in IL-17-producing cells is considered to be common across species, the immune response suppressor of IL-17-producing cells of the present invention is predicted to suppress immune responses in both mice and humans alike.
[0179] <Anti-CD96 neutralizing antibody TX111.2> Figure 19 shows that the anti-CD96 antibody TX111.2 has specificity for CD96. Figure 20 shows that the fluorescence value decreased in a concentration-dependent manner with the anti-CD96 antibody TX111.2, and that the anti-CD96 antibody TX111.2 competes with CD155, the natural ligand of CD96, for binding to CD96. In other words, the anti-CD96 antibody TX111.2 was shown to be an anti-CD96 neutralizing antibody that inhibits the binding of CD96 to CD155.
[0180] The amino acid sequences of the heavy chain variable region and light chain variable region of TX111.2 are shown in Figure 21. In Figure 21, CDRs (complementarity determining regions) 1 to 3 in the heavy chain variable region and light chain variable region are underlined.
[0181] <An experiment using anti-mouse CD96 neutralizing antibody prophylactically administered to imiquimod-induced psoriasis model mice> Photographs of the back of the imiquimod-induced psoriasis model taken 3 days after the start of application in the TX111.2 and cIg groups are shown in Figure 23. In the cIg group, the skin was reddened and scales were observed. In the TX111.2 group, the skin was reddened and scales were observed, but the degree of redness was less than that in the cIg group.
[0182] A graph comparing erythema, scale, and skin thickness on the fourth day after the start of application between the TX111.2-administered group and the cIg-administered group is shown in Figure 24. The vertical axis of the graphs for erythema and scale is the erythema score and scale score, respectively, and the vertical axis of the graph for skin thickness is skin thickness (μm). In the naive group, neither erythema nor scale was observed in either the TX111.2-administered group or the cIg-administered group.
[0183] In the imiquimod group (IMQ), both the TX111.2-administered group and the cIg-administered group had higher erythema scores than the naive group, but the TX111.2-administered group had a significantly lower erythema score than the cIg-administered group.
[0184] In the imiquimod group, both the TX111.2 and cIg groups had higher scale scores than the naive group, but the TX111.2 group had a significantly lower scale score than the cIg group.
[0185] In the imiquimod group, both the TX111.2-administered group and the cIg-administered group had thicker skin than the naive group, but the skin in the TX111.2-administered group was significantly thinner than that in the cIg-administered group. These results demonstrated that administration of TX111.2 attenuated the pathological conditions of erythema, scaling, and skin thickening induced by imiquimod.
[0186] The left side of Fig. 25 shows a HE stained photograph of a tissue specimen from the back skin of a mouse 4 days after the start of imiquimod application. In the cIg administration group, pathological conditions characteristic of psoriasis, such as epidermal thickening, parakeratosis, and infiltration of neutrophils and mononuclear cells into the dermis, were observed, but these pathological conditions were attenuated in the TX111.2 administration group. The right side of Fig. 25 shows a graph of epidermal thickness. In the cIg administration group, the epidermal thickness was about four times that of the naive group, but about twice that of the TX111.2 administration group, indicating that the epidermal thickening caused by imiquimod was attenuated.
[0187] These results demonstrated that the anti-mouse CD96 neutralizing antibody TX111.2 has a preventive effect against psoriasis.
[0188] <Therapeutic administration of anti-mouse CD96 neutralizing antibody to imiquimod-induced psoriasis model mice> Photographs of the back of the imiquimod-induced psoriasis model taken 6 days after the start of application in the TX111.2 and cIg groups are shown in Figure 27. In the cIg group, the skin was reddened and scales were observed. In the TX111.2 group, the skin was reddened and scales were observed, but the degree of redness was less than that in the cIg group.
[0189] A graph comparing erythema, scale, and skin thickness on the first day (D1) and sixth day (D6) after the start of application between the TX111.2 administration group and the cIg administration group is shown in Figure 28. The vertical axis of the erythema and scale graphs is the erythema score and scale score, respectively, and the vertical axis of the skin thickness graph is the skin thickness (μm).
[0190] On the sixth day (D6) after the start of application, the erythema scores were higher in both the TX111.2 administration group and the cIg administration group than on the first day (D1) after the start of application, but the erythema score was lower in the TX111.2 administration group than in the cIg administration group.
[0191] On the sixth day (D6) after the start of application, the scale scores, which were zero on the first day (D1) after the start of application, increased in both the TX111.2-administered group and the cIg-administered group, but the scale score was significantly lower in the TX111.2-administered group than in the cIg-administered group.
[0192] On the sixth day (D6) after the start of application, the skin in both the TX111.2-administered group and the cIg-administered group was thicker than on the first day (D1) after the start of application, but the skin in the TX111.2-administered group was significantly thinner than that in the cIg-administered group. These results demonstrated that administration of TX111.2 attenuated the pathological conditions of erythema, scaling, and skin thickening induced by imiquimod.
[0193] The left side of Figure 29 shows a HE stained photograph of a tissue specimen from the back skin of a mouse 6 days after the start of imiquimod application. In the cIg administration group, pathological conditions characteristic of psoriasis, such as epidermal thickening, parakeratosis, and infiltration of neutrophils and mononuclear cells into the dermis, were observed, but these pathological conditions were attenuated in the TX111.2 administration group. The right side of Figure 29 shows a graph of epidermal thickness, and acanthosis was significantly attenuated in the TX111.2 administration group compared to the cIg administration group.
[0194] These results demonstrated that the anti-mouse CD96 neutralizing antibody TX111.2 has a therapeutic effect on psoriasis.
[0195] <Anti-mouse CD96 neutralizing antibody administration experiment to EAE model mice> Changes in the EAE pathology score in the TX111.2-administered group and the cIg-administered group in EAE model mice are shown in Figure 31. In the cIg-administered group, the EAE pathology score increased from day 9 after EAE induction. In the TX111.2-administered group, the EAE pathology score increased on day 12 after EAE induction. The EAE pathology score in the TX111.2-administered group was always lower than that in the cIg-administered group throughout the test period.
[0196] These results demonstrated that the anti-mouse CD96 neutralizing antibody TX111.2 has preventive and therapeutic effects on multiple sclerosis.
[0197] The present inventors have newly discovered that CD96 is expressed in γδ T cells that produce IL-17. They also discovered that CD96 functions as an activating receptor in γδ T cells and CD4+ T cells, and that CD96 signaling promotes IL-17 production. They have also demonstrated, using model mice, that anti-CD96 neutralizing antibodies are effective in preventing and treating psoriasis and multiple sclerosis, which are diseases in which inflammation is induced by IL-17.
[0198] Existing IL-17 inhibitors such as anti-IL-17A antibodies and anti-IL-17A receptor antibodies suppress the immune activity caused by IL-17 throughout the body, raising concerns about side effects such as infections and neutropenia. The present inventors have clarified the mechanism by which IL-17 is produced in specific cells at the site of inflammation, and have discovered an immunosuppressant that suppresses the production of IL-17 by inhibiting part of that mechanism. The immunosuppressant of the present invention acts specifically at the site of inflammation, and is therefore expected to have fewer side effects. Industrial Applicability
[0199] According to the present invention, it is possible to provide an immune response suppressant for suppressing the immune response of IL-17-producing cells that cause pathologies such as psoriasis, and further a pharmaceutical product for treating or preventing a disease or pathology involving the immune response of IL-17-producing cells. It is also possible to provide a method for inducing an immune response in γδ T cells. It is also possible to provide a method for evaluating a pharmaceutical product for treating or preventing a disease or pathology involving the immune response of IL-17-producing cells. It is also possible to provide a method for inducing an immune response in γδ T cells to produce IL-17.
Claims
1. An agent for suppressing an immune response of IL-17-producing cells, comprising a substance that inhibits binding of CD96 to at least one protein selected from CD155 and CD111, the substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111 is a substance that specifically binds to CD96 or an inhibitor of CD96 expression; the substance that specifically binds to CD96 is an anti-CD96 antibody or an antibody fragment containing the antibody-binding site of the anti-CD96 antibody; the CD96 expression inhibitor reduces the expression of CD96 and is an siRNA, shRNA, miRNA, ribozyme, or antisense nucleic acid that specifically binds to CD96 mRNA; The immune response suppressant, wherein the IL-17-producing cells are at least one selected from γδ T cells and CD4 + T cells producing IL-17.
2. The immune response suppressor of IL-17-producing cells according to claim 1, wherein the substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111 is an anti-CD96 antibody.
3. The immune response suppressor of IL-17-producing cells according to claim 1 or 2, wherein the IL-17-producing cells are γδT cells.
4. The immune response suppressor of IL-17-producing cells according to any one of claims 1 to 3, wherein the immune response suppressor of IL-17-producing cells is an IL-17 production suppressor or an IL-22 production suppressor.
5. A pharmaceutical for treating or preventing a disease or pathology involving at least one type of immune response selected from γδ T cells and / or IL-17-producing CD4 + T cells, comprising the immune response suppressor of IL-17-producing cells according to any one of claims 1 to 4.
6. The pharmaceutical product according to claim 5, wherein the disease or pathology involving at least one type of immune response selected from the γδ T cells and / or the CD4 + T cells producing IL-17 is psoriasis, rheumatoid arthritis, atopic dermatitis, multiple sclerosis, cerebral infarction, nephritis, lung injury, or pulmonary fibrosis.
Citation Information
Patent Citations
Immune receptor modulation for treating cancer and viral infections
JP2016530268A
